Collected Works of Thomas J. Kipps

Introduction

Collected Works

1977

Kipps TJ, Benacerraf B, Dorf ME. Presence of common idiotypes on antibodies induced by glutamic acid-lysine-containing terpolymers in responder and nonresponder mice with the Ig-1b heavy chain allotype. Eur J Immunol. 1977 Dec;7(12):865-71. https://doi.org/10.1002/eji.1830071209

1978

Kipps TJ, Benacerraf B, Dorf ME. Analysis of the restricted dinitrophenyl (DNP) antibody response to the DNP conjugate of poly-(L-Glu56, L-LYS35, L-PHE9). J Immunol. 1978 Jan;120(1):46-52. https://www.jimmunol.org/content/120/1/46.long
Kipps TJ, Benacerraf B, Dorf ME. H-2 control of the magnitude and heterogeneity of the immune response. Eur J Immunol. 1978 Jun;8(6):415-23. https://doi.org/10.1002/eji.1830080609
Kipps TJ, Benacerraf B, Dorf ME. Regulation of antibody heterogeneity by suppressor T cells: diminishing suppressor T cell activity increases the number of dinitrophenyl clones in mice immunized with dinitrophenyl-poly(Glu,Lys,Phe) or dinitrophenyl-poly(Glu,Lys,Ala). Proc Natl Acad Sci U S A. 1978 Jun;75(6):2914-7. https://doi.org/10.1073/pnas.75.6.2914
Ju ST, Kipps TJ, Theze J, Benacerraf B, Dorf ME. Idiotypic analysis of anti-GAT antibodies. I. Presence of common idiotypic specificities in both responder and nonresponder mice. J Immunol. 1978 Sep;121(3):1034-9. https://www.jimmunol.org/content/121/3/1034.long

1979

Germain RN, Ju ST, Kipps TJ, Benacerraf B, Dorf ME. Shared idiotypic determinants on antibodies and T-cell-derived suppressor factor specific for the random terpolymer L-glutamic acid60-L-alanine30-L-tyrosine10. J Exp Med. 1979 Mar 1;149(3):613-22. https://doi.org/10.1084/jem.149.3.613

1980

Kipps TJ, Weinberger JZ, Benacerraf B, Dorf ME. Comparison of T and B cell reactivity to antigens under Ir gene control. J Immunol. 1980 Mar;124(3):1344-9. https://www.jimmunol.org/content/124/3/1344.long

1983

Parham P, Kipps TJ, Ward FE, Herzenberg LA. Isolation of heavy chain class switch variants of a monoclonal anti-DC1 hybridoma cell line: effective conversion of noncytotoxic IgG1 antibodies to cytotoxic IgG2 antibodies. Hum Immunol. 1983 Oct;8(2):141-51. https://doi.org/10.1016/0198-8859(83)90009-5

1985

Kipps TJ. Switching the isotype of monoclonal antibodies. In Springer TA, Ed. Hybridoma Technology in the Biosciences and Medicine. Boston, MA: Springer; 1985: 89-101. https://doi.org/10.1007/978-1-4684-4964-8_5
Kipps TJ, Parham P, Punt J, Herzenberg LA. Importance of immunoglobulin isotype in human antibody-dependent, cell-mediated cytotoxicity directed by murine monoclonal antibodies. J Exp Med. 1985 Jan 1;161(1):1-17. https://doi.org/10.1084/jem.161.1.1
Sandberg AA, Morgan R, Kipps TJ, Hecht BK, Hecht F. The Philadelphia (Ph) chromosome in leukemia. II. Variant Ph translocations in acute lymphoblastic leukemia. Cancer Genet Cytogenet. 1985 Jan 1;14(1-2):11-21. https://doi.org/10.1016/0165-4608(85)90210-9
Levitt L, Kipps TJ, Engleman EG, Greenberg PL. Human bone marrow and peripheral blood T lymphocyte depletion: efficacy and effects of both T cells and monocytes on growth of hematopoietic progenitors. Blood. 1985 Mar;65(3):663-79. https://doi.org/10.1182/blood.V65.3.663.663
Giardina SL, Schroff RW, Kipps TJ, Woodhouse CS, Abrams PG, Rager HC, Morgan AC Jr, Foon KA. The generation of monoclonal anti-idiotype antibodies to human B cell-derived leukemias and lymphomas. J Immunol. 1985 Jul;135(1):653-8. https://www.jimmunol.org/content/135/1/653.long
Lanier LL, Kipps TJ, Phillips JH. Functional properties of a unique subset of cytotoxic CD3+ T lymphocytes that express Fc receptors for IgG (CD16/Leu-11 antigen). J Exp Med. 1985 Dec 1;162(6):2089-106. https://doi.org/10.1084/jem.162.6.2089

1986

Parham P, Antonelli P, Herzenberg LA, Kipps TJ, Fuller A, Ward FE. Further studies on the epitopes of HLA-B7 defined by murine monoclonal antibodies. Hum Immunol. 1986 Jan;15(1):44-67. https://doi.org/10.1016/0198-8859(86)90316-2
Kipps TJ, Herzenberg LA. Homologous chromosome recombination generating immunoglobulin allotype and isotype switch variants. EMBO J. 1986 Feb;5(2):263-8. https://doi.org/10.1002/j.1460-2075.1986.tb04208.x

1987

Kipps TJ, Fong S, Chen PP, Miller WE, Piro LD, Carson DA. Immunoglobulin V gene utilization in CLL. In Rai KR, Gale RP, eds. Chronic Lymphocytic Leukemia: Recent Progress and Future Direction. UCLA Symposium on Molecular and Cellular Biology, New Series, vol. 59. New York, NY: Alan R. Liss; 1987:115-126.
Carson DA, Chen PP, Kipps TJ, Radoux V, Jirik F, Goldfien RD, Fox RI, Silverman GJ, Fong S. Molecular basis for the cross-reactive idiotypes on human anti-IgG autoantibodies (rheumatoid factors). Ciba Found Symp. 1987;129:123-34. https://doi.org/10.1002/9780470513484.ch9
Carson DA, Chen PP, Fox RI, Kipps TJ, Jirik F, Goldfien RD, Silverman G, Radoux V, Fong S. Rheumatoid factor and immune networks. Annu Rev Immunol. 1987;5:109-26. https://doi.org/10.1146/annurev.iy.05.040187.000545
Goldfien RD, Chen PJ, Kipps TJ, Starkebaum G, Heitzmann JG, Radoux V, Fong S, Carson DA. Genetic analysis of human B cell hybridomas expressing a cross-reactive idiotype. J Immunol. 1987 Feb 1;138(3):940-4. https://www.jimmunol.org/content/138/3/940.long
Kipps TJ, Fong S, Tomhave E, Chen PP, Goldfien RD, Carson DA. High-frequency expression of a conserved kappa light-chain variable-region gene in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 1987 May;84(9):2916-20. https://doi.org/10.1073/pnas.84.9.2916
Kipps TJ, Vaughan JH. Genetic influence on the levels of circulating CD5 B lymphocytes. J Immunol. 1987 Aug 15;139(4):1060-4. https://www.jimmunol.org/content/139/4/1060.long
Chen PP, Albrandt K, Kipps TJ, Radoux V, Liu FT, Carson DA. Isolation and characterization of human VkIII germ-line genes. Implications for the molecular basis of human VkIII light chain diversity. J Immunol. 1987 Sep 1;139(5):1727-33. https://www.jimmunol.org/content/139/5/1727.long
Carson DA, Chen PP, Kipps TJ, Radoux V, Jirik FR, Goldfien RD, Fox RI, Silverman GJ, Fong S. Idiotypic and genetic studies of human rheumatoid factors. Arthritis Rheum. 1987 Dec;30(12):1321-5. https://doi.org/10.1002/art.1780301201
Chen PP, Robbins DL, Jirik FR, Kipps TJ, Carson DA. Isolation and characterization of a light chain variable region gene for human rheumatoid factors. J Exp Med. 1987 Dec 1;166(6):1900-5. https://doi.org/10.1084/jem.166.6.1900
Waldor MK, Mitchell D, Kipps TJ, Herzenberg LA, Steinman L. Importance of immunoglobulin isotype in therapy of experimental autoimmune encephalomyelitis with monoclonal anti-CD4 antibody. J Immunol. 1987 Dec 1;139(11):3660-4. https://www.jimmunol.org/content/139/11/3660.long

1988

Kipps TJ. Immunoglobulin V gene utilization in chronic lymphocytic leukemia and non-Hodgkin’s B cell lymphomas. Nouv Rev Fr Hematol. 1988;30(5-6):293-8.
Fox RI, Fong S, Chen PP, Kipps TJ. Autoantibody production in Sjögren’s syndrome: a hypothesis regarding defects in somatic diversification of germ line encoded genes. In Vivo. 1988 Jan-Feb;2(1):47-55.
Kipps TJ, Tomhave E, Chen PP, Carson DA. Autoantibody-associated kappa light chain variable region gene expressed in chronic lymphocytic leukemia with little or no somatic mutation. Implications for etiology and immunotherapy. J Exp Med. 1988 Mar 1;167(3):840-52. https://doi.org/10.1084/jem.167.3.840
Kipps TJ, Robbins BA, Kuster P, Carson DA. Autoantibody-associated cross-reactive idiotypes expressed at high frequency in chronic lymphocytic leukemia relative to B-cell lymphomas of follicular center cell origin. Blood. 1988 Aug;72(2):422-8. https://doi.org/10.1182/blood.V72.2.422.422

1989

Kipps TJ. The CD5 B cell. Adv Immunol. 1989;47:117-85. https://doi.org/10.1016/s0065-2776(08)60663-x
Mosier DE, Gulizia RJ, Baird SM, Spector S, Spector D, Kipps TJ, Fox RI, Carson DA, Cooper N, Richman DD, et al. Studies of HIV infection and the development of Epstein-Barr virus-related B cell lymphomas following transfer of human lymphocytes to mice with severe combined immunodeficiency. Curr Top Microbiol Immunol. 1989;152:195-9. https://doi.org/10.1007/978-3-642-74974-2_23
Chen PP, Liu MF, Glass CA, Sinha S, Kipps TJ, Carson DA. Characterization of two immunoglobulin VH genes that are homologous to human rheumatoid factors. Arthritis Rheum. 1989 Jan;32(1):72-6. https://doi.org/10.1002/anr.1780320112
Liu MF, Robbins DL, Crowley JJ, Sinha S, Kozin F, Kipps TJ, Carson DA, Chen PP. Characterization of four homologous L chain variable region genes that are related to 6B6.6 idiotype positive human rheumatoid factor L chains. J Immunol. 1989 Jan 15;142(2):688-94. https://www.jimmunol.org/content/142/2/688.long
Mujoo K, Kipps TJ, Yang HM, Cheresh DA, Wargalla U, Sander DJ, Reisfeld RA. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Cancer Res. 1989 Jun 1;49(11):2857-61. https://cancerres.aacrjournals.org/content/49/11/2857.long
Kipps TJ, Tomhave E, Chen PP, Fox RI. Molecular characterization of a major autoantibody-associated cross-reactive idiotype in Sjogren’s syndrome. J Immunol. 1989 Jun 15;142(12):4261-8. https://www.jimmunol.org/content/142/12/4261.long
Pratt LF, Rassenti L, Larrick J, Robbins B, Banks PM, Kipps TJ. Ig V region gene expression in small lymphocytic lymphoma with little or no somatic hypermutation. J Immunol. 1989 Jul 15;143(2):699-705. https://www.jimmunol.org/content/143/2/699.long
Kipps TJ, Tomhave E, Pratt LF, Duffy S, Chen PP, Carson DA. Developmentally restricted immunoglobulin heavy chain variable region gene expressed at high frequency in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 1989 Aug;86(15):5913-7. ht t ps://doi.org/10.1073/pnas.86.15.5913
Carson DA, Chen PP, Kipps TJ, Roudier J, Silverman GJ, Tighe H. Regulation of rheumatoid factor synthesis. Clin Exp Rheumatol. 1989 Sep-Oct;7(Suppl 3):S69-73.

1990

Kipps TJ. Immunoglobulin idiotypes in human B cell neoplasia. Implications for pathogenesis and therapy. Chem Immunol. 1990;48:167-84. https://doi.org/10.1159/000318939
Mosier DE, Baird SM, Kirven MB, Gulizia RJ, Wilson DB, Kubayashi R, Picchio G, Garnier JL, Sullivan JL, Kipps TJ. EBV-associated B-cell lymphomas following transfer of human peripheral blood lymphocytes to mice with severe combined immune deficiency. Curr Top Microbiol Immunol. 1990;166:317-23. https://doi.org/10.1007/978-3-642-75889-8_39
Kipps TJ, Robbins BA, Carson DA. Uniform high frequency expression of autoantibody-associated crossreactive idiotypes in the primary B cell follicles of human fetal spleen. J Exp Med. 1990 Jan 1;171(1):189-96. https://doi.org/10.1084/jem.171.1.189
Adachi M, Tefferi A, Greipp PR, Kipps TJ, Tsujimoto Y. Preferential linkage of bcl-2 to immunoglobulin light chain gene in chronic lymphocytic leukemia. J Exp Med. 1990 Feb 1;171(2):559-64. https://doi.org/10.1084/jem.171.2.559
Roudier J, Silverman GJ, Chen PP, Carson DA, Kipps TJ. Intraclonal diversity in the VH genes expressed by CD5- chronic lymphocytic leukemia-producing pathologic IgM rheumatoid factor. J Immunol. 1990 Feb 15;144(4):1526-30. https://www.jimmunol.org/content/144/4/1526.long
Kipps TJ, Robbins BA, Tefferi A, Meisenholder G, Banks PM, Carson DA. CD5-positive B-cell malignancies frequently express cross-reactive idiotypes associated with IgM autoantibodies. Am J Pathol. 1990 Apr;136(4):809-16. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1877648/

1991

Carson DA, Chen PP, Silverman GJ, Kipps TJ. Immunoglobulin gene expression in systemic rheumatic diseases. Br J Rheumatol. 1991;30(Suppl 1):43-6.
Kipps TJ, Rassenti LZ, Duffy S, Kobayashi R, Martin T, Chen PP, Carson DA. Immunoglobulin gene rearrangement and expression in B-CLL. Leuk Lymphoma. 1991;5(Suppl 1):39-45. https://doi.org/10.3109/10428199109103377
Carson DA, Chen PP, Kipps TJ. New roles for rheumatoid factor. J Clin Invest. 1991 Feb;87(2):379-83. https://doi.org/10.1172/JCI115007
Axelrod O, Silverman GJ, Dev V, Kyle R, Carson DA, Kipps TJ. Idiotypic cross-reactivity of immunoglobulins expressed in Waldenström’s macroglobulinemia, chronic lymphocytic leukemia, and mantle zone lymphocytes of secondary B-cell follicles. Blood. 1991 Apr 1;77(7):1484-90. https://doi.org/10.1182/blood.V77.7.1484.1484
Kipps TJ, Duffy SF. Relationship of the CD5 B cell to human tonsillar lymphocytes that express autoantibody-associated cross-reactive idiotypes. J Clin Invest. 1991 Jun;87(6):2087-96. https://doi.org/10.1172/JCI115239
Rassenti LZ, Pratt LF, Chen PP, Carson DA, Kipps TJ. Autoantibody-encoding kappa L chain genes frequently rearranged in lambda L chain-expressing chronic lymphocytic leukemia. J Immunol. 1991 Aug 1;147(3):1060-6. https://www.jimmunol.org/content/147/3/1060.long
Pratt LF, Szubin R, Carson DA, Kipps TJ. Molecular characterization of a supratypic cross-reactive idiotype associated with IgM autoantibodies. J Immunol. 1991 Sep 15;147(6):2041-6. https://www.jimmunol.org/content/147/6/2041.long

1992

Carson DA, Wasson DB, Esparza LM, Carrera CJ, Kipps TJ, Cottam HB. Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine. Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2970-4. https://doi.org/10.1073/pnas.89.7.2970
Martin T, Duffy SF, Carson DA, Kipps TJ. Evidence for somatic selection of natural autoantibodies. J Exp Med. 1992 Apr 1;175(4):983-91. https://doi.org/10.1084/jem.175.4.983
Mosier DE, Picchio GR, Kirven MB, Garnier JL, Torbett BE, Baird SM, Kobayashi R, Kipps TJ. EBV-induced human B cell lymphomas in hu-PBL-SCID mice. AIDS Res Hum Retroviruses. 1992 May;8(5):735-40. https://doi.org/10.1089/aid.1992.8.695
Picchio GR, Kobayashi R, Kirven M, Baird SM, Kipps TJ, Mosier DE. Heterogeneity among Epstein-Barr virus-seropositive donors in the generation of immunoblastic B-cell lymphomas in SCID mice receiving human peripheral blood leukocyte grafts. Cancer Res. 1992 May 1;52(9):2468-77. https://cancerres.aacrjournals.org/content/52/9/2468.long
Kipps TJ, Rassenti LZ, Duffy S, Johnson T, Kobayashi R, Carson DA. Immunoglobulin V gene expression in CD5 B-cell malignancies. Ann N Y Acad Sci. 1992 May 4;651:373-83. https://doi.org/10.1111/j.1749-6632.1992.tb24638.x
Kipps TJ, Meisenholder G, Robbins BA. New developments in flow cytometric analyses of lymphocyte markers. Clin Lab Med. 1992 Jun;12(2):237-75. https://doi.org/10.1016/S0272-2712(18)30515-8
Grillot-Courvalin C, Brouet JC, Piller F, Rassenti LZ, Labaume S, Silverman GJ, Silberstein L, Kipps TJ. An anti-B cell autoantibody from Wiskott-Aldrich syndrome which recognizes i blood group specificity on normal human B cells. Eur J Immunol. 1992 Jul;22(7):1781-8. https://doi.org/10.1002/eji.1830220717
Kobayashi R, Picchio G, Kirven M, Meisenholder G, Baird S, Carson DA, Mosier DE, Kipps TJ. Transfer of human chronic lymphocytic leukemia to mice with severe combined immune deficiency. Leuk Res. 1992 Oct;16(10):1013-23. https://doi.org/10.1016/0145-2126(92)90081-h
Mosier DE, Picchio GR, Baird SM, Kobayashi R, Kipps TJ. Epstein-Barr virus-induced human B-cell lymphomas in SCID mice reconstituted with human peripheral blood leukocytes. Cancer Res. 1992 Oct 1;52(19 Suppl):5552s-5553s. https://cancerres.aacrjournals.org/content/52/19_Supplement/5552s.long

1993

Kipps TJ. Immunologic and therapeutic implications of anti-idiotype antibodies. In Cheson B, Ed. Chronic Lymphocytic Leukemia: Scientific Advances and Clinical Developments. New York, NY: Marcel Dekker; 1993:123-146.
Kipps TJ. Immunoglobulin genes in chronic lymphocytic leukemia. Blood Cells. 1993;19(3):615-25; discussion 631-2.
Tighe H, Chen PP, Tucker R, Kipps TJ, Roudier J, Jirik FR, Carson DA. Function of B cells expressing a human immunoglobulin M rheumatoid factor autoantibody in transgenic mice. J Exp Med. 1993 Jan 1;177(1):109-18. https://doi.org/10.1084/jem.177.1.109
Kawasaki H, Carrera CJ, Piro LD, Saven A, Kipps TJ, Carson DA. Relationship of deoxycytidine kinase and cytoplasmic 5′-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood. 1993 Feb 1;81(3):597-601. https://doi.org/10.1182/blood.V81.3.597.597
Ranheim EA, Kipps TJ. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med. 1993 Apr 1;177(4):925-35. https://doi.org/10.1084/jem.177.4.925
Rassenti LZ, Kipps TJ. Lack of extensive mutations in the VH5 genes used in common B cell chronic lymphocytic leukemia. J Exp Med. 1993 Apr 1;177(4):1039-46. https://doi.org/10.1084/jem.177.4.1039
Kipps TJ, Carson DA. Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases. Blood. 1993 May 15;81(10):2475-87. https://doi.org/10.1182/blood.V81.10.2475.2475
Raz E, Watanabe A, Baird SM, Eisenberg RA, Parr TB, Lotz M, Kipps TJ, Carson DA. Systemic immunological effects of cytokine genes injected into skeletal muscle. Proc Natl Acad Sci U S A. 1993 May 15;90(10):4523-7. https://doi.org/10.1073/pnas.90.10.4523
Kipps TJ. Gene therapy for cancer. J Hematother. 1993 Fall;2(3):367-72. https://doi.org/10.1089/scd.1.1993.2.367
Watanabe A, Raz E, Kohsaka H, Tighe H, Baird SM, Kipps TJ, Carson DA. Induction of antibodies to a kappa V region by gene immunization. J Immunol. 1993 Sep 1;151(5):2871-6. https://www.jimmunol.org/content/151/5/2871.long
Berberian L, Goodglick L, Kipps TJ, Braun J. Immunoglobulin VH3 gene products: natural ligands for HIV gp120. Science. 1993 Sep 17;261(5128):1588-91. https://doi.org/10.1126/science.7690497
Cherepakhin V, Baird SM, Meisenholder GW, Kipps TJ. Common clonal origin of chronic lymphocytic leukemia and high-grade lymphoma of Richter’s syndrome. Blood. 1993 Nov 15;82(10):3141-7. https://doi.org/10.1182/blood.V82.10.3141.3141
Kobayashi R, Rassenti LZ, Meisenholder G, Carson DA, Kipps TJ. Autoantigen inhibits apoptosis of a human B cell leukemia that produces pathogenic rheumatoid factor. J Immunol. 1993 Dec 15;151(12):7273-83. https://www.jimmunol.org/content/151/12/7273.long

1994

Lotz M, Ranheim E, Kipps TJ. Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B cells. J Exp Med. 1994 Mar 1;179(3):999-1004. https://doi.org/10.1084/jem.179.3.999
Martin T, Crouzier R, Weber JC, Kipps TJ, Pasquali JL. Structure-function studies on a polyreactive (natural) autoantibody. Polyreactivity is dependent on somatically generated sequences in the third complementarity-determining region of the antibody heavy chain. J Immunol. 1994 Jun 15;152(12):5988-96. https://www.jimmunol.org/content/152/12/5988.long
Kipps TJ. X inactivation and immunocompetence in female carriers of the X-linked hyper-IgM syndrome. J Clin Invest. 1994 Aug;94(2):469. https://doi.org/10.1172/JCI117355
Ranheim EA, Kipps TJ. Elevated expression of CD80 (B7/BB1) and other accessory molecules on synovial fluid mononuclear cell subsets in rheumatoid arthritis. Arthritis Rheum. 19 Nov;37(11):1637-46. https://doi.org/10.1002/art.1780371113
Parr TB, Johnson TA, Silberstein LE, Kipps TJ. Anti-B cell autoantibodies encoded by VH 4-21 genes in human fetal spleen do not require in vivo somatic selection. Eur J Immunol. 1994 Dec;24(12):2941-9. https://doi.org/10.1002/eji.1830241204

1995

Ranheim EA, Kipps TJ. Tumor necrosis factor-alpha facilitates induction of CD80 (B7-1) and CD54 on human B cells by activated T cells: complex regulation by IL-4, IL-10, and CD40L. Cell Immunol. 1995 Apr 1;161(2):226-35. https://doi.org/10.1006/cimm.1995.1031
Ranheim EA, Cantwell MJ, Kipps TJ. Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells. Blood. 1995 Jun 15;85(12):3556-65. https://doi.org/10.1182/blood.V85.12.3556.bloodjournal85123556
Bessudo A, Kipps TJ. Origin of high-grade lymphomas in Richter syndrome. Leuk Lymphoma. 1995 Aug;18(5-6):367-72. https://doi.org/10.3109/10428199509059634
Rassenti LZ, Kohsaka H, Kipps TJ. Analysis of immunoglobulin VH gene repertoire by an anchored PCR-ELISA. Ann N Y Acad Sci. 1995 Sep 29;764:463-73. https://doi.org/10.1111/j.1749-6632.1995.tb55866.x

1996

Silberstein LE, George A, Durdik JM, Kipps TJ. The V4-34 encoded anti-i autoantibodies recognize a large subset of human and mouse B-cells. Blood Cells Mol Dis. 1996;22(2):126-38. https://doi.org/10.1006/bcmd.1996.0020
Sasso EH, Johnson T, Kipps TJ. Expression of the immunoglobulin VH gene 51p1 is proportional to its germline gene copy number. J Clin Invest. 1996 May 1;97(9):2074-80. https://doi.org/10.1172/JCI118644
Bessudo A, Cherepakhin V, Johnson TA, Rassenti LZ, Feigal E, Kipps TJ. Favored use of immunoglobulin V(H)4 Genes in AIDS-associated B-cell lymphoma. Blood. 1996 Jul 1;88(1):252-60. https://doi.org/10.1182/blood.V88.1.252.252
Dighiero G, Kipps T, Schroeder HW, Chiorazzi N, Stevenson F, Silberstein LE, Caligaris-Cappio F, Ferrarini M. What is the CLL B-lymphocyte? Leuk Lymphoma. 1996 Oct;22 Suppl 2:13-39. https://doi.org/10.3109/10428199609102700
Sharma S, Cantwell M, Kipps TJ, Friedmann T. Efficient infection of a human T-cell line and of human primary peripheral blood leukocytes with a pseudotyped retrovirus vector. Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11842-7. https://doi.org/10.1073/pnas.93.21.11842
Fong TC, Wu Y, Kipps TJ. Identification of a promoter element that regulates tissue-specific expression of the human CD80 (B7.1) gene. J Immunol. 1996 Nov 15;157(10):4442-50. https://www.jimmunol.org/content/157/10/4442.long
Cantwell MJ, Sharma S, Friedmann T, Kipps TJ. Adenovirus vector infection of chronic lymphocytic leukemia B cells. Blood. 1996 Dec 15;88(12):4676-83. https://doi.org/10.1182/blood.V88.12.4676.bloodjournal88124676
Kohsaka H, Carson DA, Rassenti LZ, Ollier WE, Chen PP, Kipps TJ, Miyasaka N. The human immunoglobulin V(H) gene repertoire is genetically controlled and unaltered by chronic autoimmune stimulation. J Clin Invest. 1996 Dec 15;98(12):2794-800. https://doi.org/10.1172/JCI119106

1997

Kipps TJ. Human B cell biology. Int Rev Immunol. 1997;15(3-4):243-64. https://doi.org/10.3109/08830189709068178
Johnson TA, Rassenti LZ, Kipps TJ. Ig VH1 genes expressed in B cell chronic lymphocytic leukemia exhibit distinctive molecular features. J Immunol. 1997 Jan 1;158(1):235-46. https://www.jimmunol.org/content/158/1/235.long
Sasso EH, Johnson T, Kipps TJ. Expression of an Ig VH gene, 51p1, is proportional to its germline gene copy number. Ann N Y Acad Sci. 1997 Apr 5;815:478-80. https://doi.org/10.1111/j.1749-6632.1997.tb52108.x
Rassenti LZ, Kipps TJ. Lack of allelic exclusion in B cell chronic lymphocytic leukemia. J Exp Med. 1997 Apr 21;185(8):1435-45. https://doi.org/10.1084/jem.185.8.1435
Kipps TJ. Chronic lymphocytic leukemia. Curr Opin Hematol. 1997 Jul;4(4):268-76. https://doi.org/10.1097/00062752-199704040-00008
Cantwell M, Hua T, Pappas J, Kipps TJ. Acquired CD40-ligand deficiency in chronic lymphocytic leukemia. Nat Med. 1997 Sep;3(9):984-9. https://doi.org/10.1038/nm0997-984
Cantwell MJ, Hua T, Zvaifler NJ, Kipps TJ. Deficient Fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis. Arthritis Rheum. 1997 Sep;40(9):1644-52. https://doi.org/10.1002/art.1780400914
Kipps TJ. Signal transduction pathways and mechanisms of apoptosis in CLL B-lymphocytes: their role in CLL pathogenesis. Hematol Cell Ther. 1997 Nov;39(Suppl 1):S17-27. https://doi.org/10.1007/s00282-997-0017-4
Mendoza RB, Cantwell MJ, Kipps TJ. Immunostimulatory effects of a plasmid expressing CD40 ligand (CD154) on gene immunization. J Immunol. 1997 Dec 15;159(12):5777-81. https://www.jimmunol.org/content/159/12/5777.long
Wu Y, Kipps TJ. Deoxyribonucleic acid vaccines encoding antigens with rapid proteasome-dependent degradation are highly efficient inducers of cytolytic T lymphocytes. J Immunol. 1997 Dec 15;159(12):6037-43. https://www.jimmunol.org/content/159/12/6037.long

1998

Mendoza RB, Kipps TJ. Genetic adjuvants for DNA immunization. In Raz E, Ed. Gene Vaccination: Theory and Practice. Berlin: Springer-Verlag; 1998: 31-38. https://doi.org/10.1007/978-3-642-46867-4_4
Wu Y, Kipps TJ. DNA vaccines with rapid intracellular degradation are more effective for inducing CTL. In Raz E, Ed. Gene Vaccination: Theory and Practice. Berlin: Springer-Verlag; 1998: 51-57. https://doi.org/10.1007/978-3-642-46867-4_6
Kato K, Cantwell MJ, Sharma S, Kipps TJ. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest. 1998 Mar 1;101(5):1133-41. https://doi.org/10.1172/JCI1472
Chen Y, Hu D, Eling DJ, Robbins J, Kipps TJ. DNA vaccines encoding full- length or truncated Neu induce protective immunity against Neu-expressing mammary tumors. Cancer Res. 1998 May 1;58(9):1965-71. https://cancerres.aacrjournals.org/content/58/9/1965.long
Bessudo A, Rassenti L, Havlir D, Richman D, Feigal E, Kipps TJ. Aberrant and unstable expression of immunoglobulin genes in persons infected with human immunodeficiency virus. Blood. 1998 Aug 15;92(4):1317-23. https://doi.org/10.1182/blood.V92.4.1317
Kipps TJ. Chronic lymphocytic leukemia. Curr Opin Hematol. 1998 Jul;5(4):244-53. https://doi.org/10.1097/00062752-199807000-00003
Fais F, Ghiotto F, Hashimoto S, Sellars B, Valetto A, Allen SL, Schulman P, Vinciguerra VP, Rai K, Rassenti LZ, Kipps TJ, Dighiero G, Schroeder HW Jr, Ferrarini M, Chiorazzi N. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest. 1998 Oct 15;102(8):1515-25. https://doi.org/10.1172/JCI3009

1999

Wierda WG, Kipps TJ. Chronic lymphocytic leukemia. Curr Opin Hematol. 1999 Jul;6(4):253-61. https://doi.org/10.1097/00062752-199907000-00010
Hu D, Kipps TJ. Reduction in mitochondrial membrane potential is an early event in Fas-independent CTL-mediated apoptosis. Cell Immunol. 1999 Jul 10;195(1):43-52. https://doi.org/10.1006/cimm.1999.1513
Kato K, Santana-Sahagún E, Rassenti LZ, Weisman MH, Tamura N, Kobayashi S, Hashimoto H, Kipps TJ. The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest. 1999 Oct;104(7):947-55. https://doi.org/10.1172/JCI7014
Kipps TJ. Future strategies toward the cure of indolent B-cell malignancies. Molecular genetic approaches. Semin Hematol. 1999 Oct;36(4 Suppl 5):3-8.
Burger JA, Burger M, Kipps TJ. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood. 1999 Dec 1;94(11):3658-67. https://doi.org/10.1182/blood.V94.11.3658

2000

Kipps TJ. Genetic engineering strategies for hematologic malignancies. Genet Eng (N Y). 2000;22:197-207. https://doi.org/10.1007/978-1-4615-4199-8_11
Burger JA, Baird SM, Powell HC, Sharma S, Eling DJ, Kipps TJ. Local and systemic effects after adenoviral transfer of the murine granulocyte-macrophage colony-stimulating factor gene into mice. Br J Haematol. 2000 Mar;108(3):641-52. https://doi.org/10.1046/j.1365-2141.2000.01863.x
Kovarik J, Martinez X, Pihlgren M, Bozzotti P, Tao MH, Kipps TJ, Wild TF, Lambert PH, Siegrist CA. Limitations of in vivo IL-12 supplementation strategies to induce Th1 early life responses to model viral and bacterial vaccine antigens. Virology. 2000 Mar 1;268(1):122-31. https://doi.org/10.1006/viro.1999.0159
Rassenti LZ, Kipps TJ. Expression of Ig-β (CD79b) by chronic lymphocytic leukemia B cells that lack immunoglobulin heavy-chain allelic exclusion. Blood. 2000 Apr 15;95(8):2725-7. https://doi.org/10.1182/blood.V95.8.2725
Kipps TJ. Genetics of chronic lymphocytic leukaemia. Hematol Cell Ther. 2000 Jun;42(1):5-14. https://doi.org/10.1007/s00282-000-0005-4
Chu P, Wierda WG, Kipps TJ. CD40 activation does not protect chronic lymphocytic leukemia B cells from apoptosis induced by cytotoxic T lymphocytes. Blood. 2000 Jun 15;95(12):3853-8. https://doi.org/10.1182/blood.V95.12.3853
Eling DJ, Johnson PA, Sharma S, Tufaro F, Kipps TJ. Chronic lymphocytic leukemia B cells are highly sensitive to infection by herpes simplex virus-1 via herpesvirus-entry-mediator A. Gene Ther. 2000 Jul;7(14):1210-6. https://doi.org/10.1038/sj.gt.3301241
Kipps TJ. Chronic lymphocytic leukemia. Curr Opin Hematol. 2000 Jul;7(4):223-34. https://doi.org/10.1097/00062752-200007000-00005
Spear MA, Sun F, Eling DJ, Gilpin E, Kipps TJ, Chiocca EA, Bouvet M. Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation. Cancer Gene Ther. 2000 Jul;7(7):1051-9. https://doi.org/10.1038/sj.cgt.7700208
Wierda WG, Kipps TJ. Gene therapy of hematologic malignancies. Semin Oncol. 2000 Oct;27(5):502-11.
Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell’Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood. 2000 Oct 15;96(8):2655-63. https://doi.org/10.1182/blood.V96.8.2655
Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE, Kipps TJ. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood. 2000 Nov 1;96(9):2917-24. https://doi.org/10.1182/blood.V96.9.2917
Zapata JM, Krajewska M, Krajewski S, Kitada S, Welsh K, Monks A, McCloskey N, Gordon J, Kipps TJ, Gascoyne RD, Shabaik A, Reed JC. TNFR-associated factor family protein expression in normal tissues and lymphoid malignancies. J Immunol. 2000 Nov 1;165(9):5084-96. https://doi.org/10.4049/jimmunol.165.9.5084
Kipps TJ, Chu P, Wierda WG. Immunogenetic therapy for B-cell malignancies. Semin Oncol. 2000 Dec;27(6 Suppl 12):104-9.

2001

Kipps TJ. Genetic approaches to the therapy of chronic lymphocytic leukemia. In Cheson B, Ed. Chronic Lymphocytic Leukemia. Second edition. New York, NY: Marcel Dekker; 2001; 175-193.
Widhopf GF 2nd, Kipps TJ. Normal B cells express 51p1-encoded Ig heavy chains that are distinct from those expressed by chronic lymphocytic leukemia B cells. J Immunol. 2001 Jan 1;166(1):95-102. https://doi.org/10.4049/jimmunol.166.1.95
Burger JA, Zvaifler NJ, Tsukada N, Firestein GS, Kipps TJ. Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell-derived factor-1- and CD106 (VCAM-1)-dependent mechanism. J Clin Invest. 2001 Feb;107(3):305-15. https://doi.org/10.1172/JCI11092
Burger JA, Mendoza RB, Kipps TJ. Plasmids encoding granulocyte-macrophage colony-stimulating factor and CD154 enhance the immune response to genetic vaccines. Vaccine. 2001 Feb 28;19(15-16):2181-9. https://doi.org/10.1016/s0264-410x(00)00382-0
Mabuchi H, Fujii H, Calin G, Alder H, Negrini M, Rassenti L, Kipps TJ, Bullrich F, Croce CM. Cloning and characterization of CLLD6, CLLD7, and CLLD8, novel candidate genes for leukemogenesis at chromosome 13q14, a region commonly deleted in B-cell chronic lymphocytic leukemia. Cancer Res. 2001 Apr 1;61(7):2870-7. https://cancerres.aacrjournals.org/content/61/7/2870.long
Cantwell MJ, Wierda WG, Lossos IS, Levy R, Kipps TJ. T cell activation following infection of primary follicle center lymphoma B cells with adenovirus encoding CD154. Leukemia. 2001 Sep;15(9):1451-7. https://doi.org/10.1038/sj.leu.2402208
Bullrich F, Fujii H, Calin G, Mabuchi H, Negrini M, Pekarsky Y, Rassenti L, Alder H, Reed JC, Keating MJ, Kipps TJ, Croce CM. Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene. Cancer Res. 2001 Sep 15;61(18):6640-8. https://cancerres.aacrjournals.org/content/61/18/6640.long
Hua XH, Genini D, Gussio R, Tawatao R, Shih H, Kipps TJ, Carson DA, Leoni LM. Biochemical genetic analysis of indanocine resistance in human leukemia. Cancer Res. 2001 Oct 1;61(19):7248-54. https://cancerres.aacrjournals.org/content/61/19/7248.long
Tamura N, Kobayashi S, Kato K, Bando H, Haruta K, Oyanagi M, Kuriyama M, Kipps TJ, Hashimoto H. Soluble CD154 in rheumatoid arthritis: elevated plasma levels in cases with vasculitis. J Rheumatol. 2001 Dec;28(12):2583-90. http://www.jrheum.org/content/28/12/2583.long
Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, Yang L, Pickeral OK, Rassenti LZ, Powell J, Botstein D, Byrd JC, Grever MR, Chiorazzi N, Wilson WH, Kipps TJ, Brown PO, Staudt LM. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001 Dec 3;194(11):1639-47. https://doi.org/10.1084/jem.194.11.1639

2002

Zhong RK, Rassenti LZ, Kipps TJ, Chen J, Law P, Yu JF, Ball ED. Sequential modulation of growth factors: a novel strategy for adoptive immunotherapy of acute myeloid leukemia. Biol Blood Marrow Transplant. 2002;8(10):557-68. https://doi.org/10.1053/bbmt.2002.v8.pm12434951
Kipps TJ. Advances in classification and therapy of indolent B-cell malignancies. Semin Oncol. 2002 Feb;29(1 Suppl 2):98-104. https://doi.org/10.1053/sonc.2002.30146
Tsukada N, Burger JA, Zvaifler NJ, Kipps TJ. Distinctive features of “nurselike” cells that differentiate in the context of chronic lymphocytic leukemia. Blood. 2002 Feb 1;99(3):1030-7. https://doi.org/10.1182/blood.v99.3.1030
Burger JA, Kipps TJ. Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells. Leuk Lymphoma. 2002 Mar;43(3):461-6. https://doi.org/10.1080/10428190290011921
Chu P, Deforce D, Pedersen IM, Kim Y, Kitada S, Reed JC, Kipps TJ. Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3854-9. Epub 2002 Mar 12. https://doi.org/10.1073/pnas.022604399
Bashey A, Cantwell MJ, Kipps TJ. Adenovirus transduction to effect CD40 signalling improves the immune stimulatory activity of myeloma cells. Br J Haematol. 2002 Aug;118(2):506-13. https://doi.org/10.1046/j.1365-2141.2002.03603.x
Kipps TJ. Immune and cell therapy of hematologic malignancies. Int J Hematol. 2002 Aug;76 (Suppl 1):269-73. https://doi.org/10.1007/BF03165260
Pedersen IM, Kitada S, Leoni LM, Zapata JM, Karras JG, Tsukada N, Kipps TJ, Choi YS, Bennett F, Reed JC. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood. 2002 Sep 1;100(5):1795-801. https://doi.org/10.1182/blood.V100.5.1795.h81702001795_1795_1801
Tolba KA, Bowers WJ, Eling DJ, Casey AE, Kipps TJ, Federoff HJ, Rosenblatt JD. HSV amplicon-mediated delivery of LIGHT enhances the antigen-presenting capacity of chronic lymphocytic leukemia. Mol Ther. 2002 Oct;6(4):455-63. https://doi.org/10.1006/mthe.2002.0693
Pedersen IM, Kitada S, Schimmer A, Kim Y, Zapata JM, Charboneau L, Rassenti L, Andreeff M, Bennett F, Sporn MB, Liotta LD, Kipps TJ, Reed JC. The triterpenoid CDDO induces apoptosis in refractory CLL B cells. Blood. 2002 Oct 15;100(8):2965-72. https://doi.org/10.1182/blood-2002-04-1174
Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F, Croce CM. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9. Epub 2002 Nov 14. https://doi.org/10.1073/pnas.242606799
Chen L, Widhopf G, Huynh L, Rassenti L, Rai KR, Weiss A, Kipps TJ. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2002 Dec 15;100(13):4609-14. Epub 2002 Aug 8. https://doi.org/10.1182/blood-2002-06-1683

2003

Greaves AW, Payne PR, Rassenti L, Kipps TJ. CRC Tissue Core Management System (TCMS): integration of basic science and clinical data for translational research. AMIA Annu Symp Proc. 2003;2003:853. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1480018/
Payne PR, Greaves AW, Kipps TJ. CRC Clinical Trials Management System (CTMS): an integrated information management solution for collaborative clinical research. AMIA Annu Symp Proc. 2003;2003:967. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1480351/
Keating MJ, Chiorazzi N, Messmer BT, Damle RN, Allen SL, Rai KR, Ferrarini M, Kipps TJ. Biology and treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2003:153-75. https://doi.org/10.1182/asheducation-2003.1.153
Battle TE, Wierda WG, Rassenti LZ, Zahrieh D, Neuberg D, Kipps TJ, Frank DA. In vivo activation of signal transducer and activator of transcription 1 after CD154 gene therapy for chronic lymphocytic leukemia is associated with clinical and immunologic response. Clin Cancer Res. 2003 Jun;9(6):2166-72. https://clincancerres.aacrjournals.org/content/9/6/2166.long
Wu CC, Castro JE, Motta M, Cottam HB, Kyburz D, Kipps TJ, Corr M, Carson DA. Selection of oligonucleotide aptamers with enhanced uptake and activation of human leukemia B cells. Hum Gene Ther. 2003 Jun 10;14(9):849-60. https://doi.org/10.1089/104303403765701141
Kipps TJ. Immunobiology of chronic lymphocytic leukemia. Curr Opin Hematol. 2003 Jul;10(4):312-8. https://doi.org/10.1097/00062752-200307000-00010
Rieger R, Kipps TJ. CpG oligodeoxynucleotides enhance the capacity of adenovirus-mediated CD154 gene transfer to generate effective B-cell lymphoma vaccines. Cancer Res. 2003 Jul 15;63(14):4128-35. https://cancerres.aacrjournals.org/content/63/14/4128.long
Burger M, Glodek A, Hartmann T, Schmitt-Gräff A, Silberstein LE, Fujii N, Kipps TJ, Burger JA. Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene. 2003 Nov 6;22(50):8093-101. https://doi.org/10.1038/sj.onc.1207097

2004

Castro JE, Kipps TJ. Gene therapy of chronic lymphocytic leukemia. In Faguet GB, Ed. Chronic Lymphocytic Leukemia: Molecular Genetics, Biology, Diagnosis, and Management. Totowa, NJ: Humana Press; 2004: 329-340. https://doi.org/10.1007/978-1-59259-412-2_18
Widhopf GF 2nd, Brinson DC, Kipps TJ, Tighe H. Transgenic expression of a human polyreactive Ig expressed in chronic lymphocytic leukemia generates memory-type B cells that respond to nonspecific immune activation. J Immunol. 2004 Feb 15;172(4):2092-9. https://doi.org/10.4049/jimmunol.172.4.2092
Becattini B, Kitada S, Leone M, Monosov E, Chandler S, Zhai D, Kipps TJ, Reed JC, Pellecchia M. Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L). Chem Biol. 2004 Mar;11(3):389-95. https://doi.org/10.1016/j.chembiol.2004.02.020
Keating M, Coutré S, Rai K, Osterborg A, Faderl S, Kennedy B, Kipps T, Bodey G, Byrd JC, Rosen S, Dearden C, Dyer MJ, Hillmen P. Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma. 2004 Mar;4(4):220-7. https://doi.org/10.3816/clm.2004.n.002
Lu D, Zhao Y, Tawatao R, Cottam HB, Sen M, Leoni LM, Kipps TJ, Corr M, Carson DA. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3118-23. Epub 2004 Feb 18. https://doi.org/10.1073/pnas.0308648100
Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, Shimizu M, Cimmino A, Zupo S, Dono M, Dell’Aquila ML, Alder H, Rassenti L, Kipps TJ, Bullrich F, Negrini M, Croce CM. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11755-60. Epub 2004 Jul 29. https://doi.org/10.1073/pnas.0404432101
Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG, Neuberg DS, Flinn IW, Rai KR, Byrd JC, Kay NE, Greaves A, Weiss A, Kipps TJ. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004 Aug 26;351(9):893-901. https://doi.org/10.1056/NEJMoa040857
Albitar M, Do KA, Johnson MM, Giles FJ, Jilani I, O’Brien S, Cortes J, Thomas D, Rassenti LZ, Kipps TJ, Kantarjian HM, Keating M. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer. 2004 Sep 1;101(5):999-1008. https://doi.org/10.1002/cncr.20477
Widhopf GF 2nd, Rassenti LZ, Toy TL, Gribben JG, Wierda WG, Kipps TJ. Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood. 2004 Oct 15;104(8):2499-504. Epub 2004 Jun 24. https://doi.org/10.1182/blood-2004-03-0818

2005

Ohata J, Zvaifler NJ, Nishio M, Boyle DL, Kalled SL, Carson DA, Kipps TJ. Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol. 2005 Jan 15;174(2):864-70. https://doi.org/10.4049/jimmunol.174.2.864
Mackus WJ, Kater AP, Grummels A, Evers LM, Hooijbrink B, Kramer MH, Castro JE, Kipps TJ, van Lier RA, van Oers MH, Eldering E. Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation. Leukemia. 2005 Mar;19(3):427-34. https://doi.org/10.1038/sj.leu.2403623
Chen L, Apgar J, Huynh L, Dicker F, Giago-McGahan T, Rassenti L, Weiss A, Kipps TJ. ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood. 2005 Mar 1;105(5):2036-41. Epub 2004 Oct 28. https://doi.org/10.1182/blood-2004-05-1715
Dicker F, Kater AP, Fukuda T, Kipps TJ. Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells. Blood. 2005 Apr 15;105(8):3193-8. Epub 2004 Aug 31. https://doi.org/10.1182/blood-2003-10-3684
Calin GA, Trapasso F, Shimizu M, Dumitru CD, Yendamuri S, Godwin AK, Ferracin M, Bernardi G, Chatterjee D, Baldassarre G, Rattan S, Alder H, Mabuchi H, Shiraishi T, Hansen LL, Overgaard J, Herlea V, Mauro FR, Dighiero G, Movsas B, Rassenti L, Kipps T, Baffa R, Fusco A, Mori M, Russo G, Liu CG, Neuberg D, Bullrich F, Negrini M, Croce CM. Familial cancer associated with a polymorphism in ARLTS1. N Engl J Med. 2005 Apr 21;352(16):1667-76. https://doi.org/10.1056/NEJMoa042280
Raval A, Lucas DM, Matkovic JJ, Bennett KL, Liyanarachchi S, Young DC, Rassenti L, Kipps TJ, Grever MR, Byrd JC, Plass C. TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia. J Clin Oncol. 2005 Jun 10;23(17):3877-85. Epub 2005 Apr 4. https://doi.org/10.1200/JCO.2005.02.196
Nishio M, Endo T, Tsukada N, Ohata J, Kitada S, Reed JC, Zvaifler NJ, Kipps TJ. Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood. 2005 Aug 1;106(3):1012-20. Epub 2005 Apr 28. https://doi.org/10.1182/blood-2004-03-0889
Kater AP, Dicker F, Mangiola M, Welsh K, Houghten R, Ostresh J, Nefzi A, Reed JC, Pinilla C, Kipps TJ. Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis. Blood. 2005 Sep 1;106(5):1742-8. Epub 2005 May 24. https://doi.org/10.1182/blood-2005-02-0695
Burger M, Hartmann T, Krome M, Rawluk J, Tamamura H, Fujii N, Kipps TJ, Burger JA. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood. 2005 Sep 1;106(5):1824-30. Epub 2005 May 19. https://doi.org/10.1182/blood-2004-12-4918
Wierda WG, Kipps TJ, Keating MJ. Novel immune-based treatment strategies for chronic lymphocytic leukemia. J Clin Oncol. 2005 Sep 10;23(26):6325-32. https://doi.org/10.1200/JCO.2005.05.008
Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9. Epub 2005 Sep 15. https://doi.org/10.1073/pnas.0506654102
Messmer D, Kipps TJ. Treatment of solid tumors with immunotoxins. Breast Cancer Res. 2005 Oct;7(5):184-6. Epub 2005 Jul 12. https://doi.org/10.1186/bcr1284
Motta M, Rassenti L, Shelvin BJ, Lerner S, Kipps TJ, Keating MJ, Wierda WG. Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia. 2005 Oct;19(10):1788-93. https://doi.org/10.1038/sj.leu.2403907
Castro JE, Prada CE, Loria O, Kamal A, Chen L, Burrows FJ, Kipps TJ. ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia. Blood. 2005 Oct 1;106(7):2506-12. Epub 2005 Jun 21. https://doi.org/10.1182/blood-2005-03-1099
Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, Iuliano R, Palumbo T, Pichiorri F, Roldo C, Garzon R, Sevignani C, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005 Oct 27;353(17):1793-801. https://doi.org/10.1056/NEJMoa050995
Flinn IW, Byrd JC, Bartlett N, Kipps T, Gribben J, Thomas D, Larson RA, Rai K, Petric R, Ramon-Suerez J, Gabrilove J, Grever MR. Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res. 2005 Nov;29(11):1253-7. https://doi.org/10.1016/j.leukres.2005.03.010
Messmer D, Kipps TJ. CD154 gene therapy for human B-cell malignancies. Ann N Y Acad Sci. 2005 Dec;1062:51-60. https://doi.org/10.1196/annals.1358.008

2006

Kipps TJ. Immunoglobulin Genes. In Detrick B, Hamilton R, Folds J, Eds. Manual of Molecular and Clinical Laboratory Immunology. 7th Edition. ASM Press: Washington, DC; 2006: 56-68. https://doi.org/10.1128/9781555815905.ch7
Binet JL, Caligaris-Cappio F, Catovsky D, Cheson B, Davis T, Dighiero G, Döhner H, Hallek M, Hillmen P, Keating M, Montserrat E, Kipps TJ, Rai K. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood. 2006 Feb 1;107(3):859-61. Epub 2005 Oct 13. https://doi.org/10.1182/blood-2005-04-1677
Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood. 2006 Mar 1;107(5):1761-7. Epub 2005 Nov 3. https://doi.org/10.1182/blood-2005-08-3182
Castro JE, Prada CE, Aguillon RA, Kitada S, Fukuda T, Motta M, Wu C, Dicker F, Sun G, Wang JY, Carson DA, Reed JC, Kipps TJ. Thymidine-phosphorothioate oligonucleotides induce activation and apoptosis of CLL cells independently of CpG motifs or BCL-2 gene interference. Leukemia. 2006 Apr;20(4):680-8. https://doi.org/10.1038/sj.leu.2404144
Rassenti LZ, Kipps TJ. Clinical utility of assessing ZAP-70 and CD38 in chronic lymphocytic leukemia. Cytometry B Clin Cytom. 2006 Jul 15;70(4):209-13. https://doi.org/10.1002/cyto.b.20129
Dicker F, Kater AP, Prada CE, Fukuda T, Castro JE, Sun G, Wang JY, Kipps TJ. CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53. Blood. 2006 Nov 15;108(10):3450-7. Epub 2006 Jun 1. https://doi.org/10.1182/blood-2006-04-017749
Pekarsky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V, Volinia S, Alder H, Liu CG, Rassenti L, Calin GA, Hagan JP, Kipps T, Croce CM. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res. 2006 Dec 15;66(24):11590-3. https://doi.org/10.1158/0008-5472.CAN-06-3613

2007

Ise T, Nagata S, Kreitman RJ, Wilson WH, Wayne AS, Stetler-Stevenson M, Bishop MR, Scheinberg DA, Rassenti L, Kipps TJ, Kyle RA, Jelinek DF, Pastan I. Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma. Leukemia. 2007 Jan;21(1):169-74. Epub 2006 Oct 19. https://doi.org/10.1038/sj.leu.2404445
Endo T, Nishio M, Enzler T, Cottam HB, Fukuda T, James DF, Karin M, Kipps TJ. BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway. Blood. 2007 Jan 15;109(2):703-10. Epub 2006 Sep 14. https://doi.org/10.1182/blood-2006-06-027755
James DF, Kipps TJ. Alemtuzumab in chronic lymphocytic leukemia. Future Oncol. 2007 Feb;3(1):29-42. https://doi.org/10.2217/14796694.3.1.29
Kato K, Chu P, Takahashi S, Hamada H, Kipps TJ. Metalloprotease inhibitors block release of soluble CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells. Exp Hematol. 2007 Mar;35(3):434-42. https://doi.org/10.1016/j.exphem.2006.10.018
Rawstron AC, Villamor N, Ritgen M, Böttcher S, Ghia P, Zehnder JL, Lozanski G, Colomer D, Moreno C, Geuna M, Evans PA, Natkunam Y, Coutre SE, Avery ED, Rassenti LZ, Kipps TJ, Caligaris-Cappio F, Kneba M, Byrd JC, Hallek MJ, Montserrat E, Hillmen P. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia. 2007 May;21(5):956-64. Epub 2007 Mar 15. https://doi.org/10.1038/sj.leu.2404584
Raval A, Tanner SM, Byrd JC, Angerman EB, Perko JD, Chen SS, Hackanson B, Grever MR, Lucas DM, Matkovic JJ, Lin TS, Kipps TJ, Murray F, Weisenburger D, Sanger W, Lynch J, Watson P, Jansen M, Yoshinaga Y, Rosenquist R, de Jong PJ, Coggill P, Beck S, Lynch H, de la Chapelle A, Plass C. Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell. 2007 Jun 1;129(5):879-90. https://doi.org/10.1016/j.cell.2007.03.043
Byrd JC, O’Brien S, Flinn IW, Kipps TJ, Weiss M, Rai K, Lin TS, Woodworth J, Wynne D, Reid J, Molina A, Leigh B, Harris S. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4448-55. https://doi.org/10.1158/1078-0432.CCR-06-1463
Calin GA, Liu CG, Ferracin M, Hyslop T, Spizzo R, Sevignani C, Fabbri M, Cimmino A, Lee EJ, Wojcik SE, Shimizu M, Tili E, Rossi S, Taccioli C, Pichiorri F, Liu X, Zupo S, Herlea V, Gramantieri L, Lanza G, Alder H, Rassenti L, Volinia S, Schmittgen TD, Kipps TJ, Negrini M, Croce CM. Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell. 2007 Sep;12(3):215-29. https://doi.org/10.101 6 /j.ccr.2007.07.027
Kipps TJ. The B-cell receptor and ZAP-70 in chronic lymphocytic leukemia. Best Pract Res Clin Haematol. 2007 Sep;20(3):415-24. https://doi.org/10.1016/j.beha.2007.04.001
Wierda WG, Kipps TJ. Gene therapy and active immune therapy of hematologic malignancies. Best Pract Res Clin Haematol. 2007 Sep;20(3):557-68. https://doi.org/10.1016/j.beha.2007.03.006
Kater AP, van Oers MH, Kipps TJ. Cellular immune therapy for chronic lymphocytic leukemia. Blood. 2007 Oct 15;110(8):2811-8. Epub 2007 Jul 16. https://doi.org/10.1182/blood-2007-01-068932
Sellick GS, Goldin LR, Wild RW, Slager SL, Ressenti L, Strom SS, Dyer MJ, Mauro FR, Marti GE, Fuller S, Lyttelton M, Kipps TJ, Keating MJ, Call TG, Catovsky D, Caporaso N, Houlston RS. A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemia. Blood. 2007 Nov 1;110(9):3326-33. Epub 2007 Aug 8. https://doi.org/10.1182/blood-2007-05-091561
Nicoloso MS, Kipps TJ, Croce CM, Calin GA. MicroRNAs in the pathogeny of chronic lymphocytic leukaemia. Br J Haematol. 2007 Dec;139(5):709-16. https://doi.org/10.1111/j.1365-2141.2007.06868.x
Kipps TJ. Value of computed tomography in the monitoring of patients with chronic lymphocytic leukemia. J Clin Oncol. 2007 Dec 10;25(35):5556. Epub 2007 Nov 5. https://doi.org/10.1200/JCO.2007.13.7844

2008

Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O’Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter’s syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2008 Jan 10;26(2):196-203. https://doi.org/10.1200/JCO.2007.11.8513
Fukuda T, Chen L, Endo T, Tang L, Lu D, Castro JE, Widhopf GF 2nd, Rassenti LZ, Cantwell MJ, Prussak CE, Carson DA, Kipps TJ. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3047-52. Epub 2008 Feb 19. https://doi.org/10.1073/pnas.0712148105
Chen L, Huynh L, Apgar J, Tang L, Rassenti L, Weiss A, Kipps TJ. ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. Blood. 2008 Mar 1;111(5):2685-92. Epub 2007 Nov 29. https://doi.org/10.1182/blood-2006-12-062265
Widhopf GF 2nd, Goldberg CJ, Toy TL, Rassenti LZ, Wierda WG, Byrd JC, Keating MJ, Gribben JG, Rai KR, Kipps TJ. Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3. Blood. 2008 Mar 15;111(6):3137-44. Epub 2007 Aug 3. https://doi.org/10.1182/blood-2007-02-073130
Calin GA, Cimmino A, Fabbri M, Ferracin M, Wojcik SE, Shimizu M, Taccioli C, Zanesi N, Garzon R, Aqeilan RI, Alder H, Volinia S, Rassenti L, Liu X, Liu CG, Kipps TJ, Negrini M, Croce CM. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci U S A. 2008 Apr 1;105(13):5166-71. Epub 2008 Mar 24. https://doi.org/10.1073/pnas.0800121105
Ghia EM, Jain S, Widhopf GF 2nd, Rassenti LZ, Keating MJ, Wierda WG, Gribben JG, Brown JR, Rai KR, Byrd JC, Kay NE, Greaves AW, Kipps TJ. Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. Blood. 2008 May 15;111(10):5101-8. Epub 2008 Mar 7. https://doi.org/10.1182/blood-2007-12-130229
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008 Jun 15;111(12):5446-56. Epub 2008 Jan 23. https://doi.org/10.1182/blood-2007-06-093906
Kohlmann A, Kipps TJ, Rassenti LZ, Downing JR, Shurtleff SA, Mills KI, Gilkes AF, Hofmann WK, Basso G, Dell’orto MC, Foà R, Chiaretti S, De Vos J, Rauhut S, Papenhausen PR, Hernández JM, Lumbreras E, Yeoh AE, Koay ES, Li R, Liu WM, Williams PM, Wieczorek L, Haferlach T. An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase. Br J Haematol. 2008 Sep;142(5):802-7. https://doi.org/10.1111/j.1365-2141.2008.07261.x
Kipps TJ. Genomic complexity in chronic lymphocytic leukemia. Blood. 2008 Sep 1;112(5):1550. https://doi.org/10.1182/blood-2008-06-156729
Rassenti LZ, Jain S, Keating MJ, Wierda WG, Grever MR, Byrd JC, Kay NE, Brown JR, Gribben JG, Neuberg DS, He F, Greaves AW, Rai KR, Kipps TJ. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood. 2008 Sep 1;112(5):1923-30. Epub 2008 Jun 24. https://doi.org/10.1182/blood-2007-05-092882
Castro JE, Sandoval-Sus JD, Bole J, Rassenti L, Kipps TJ. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia. 2008 Nov;22(11):2048-53. Epub 2008 Aug 28. https://doi.org/10.1038/leu.2008.214
Zhang L, Murray F, Zahno A, Kanter JR, Chou D, Suda R, Fenlon M, Rassenti L, Cottam H, Kipps TJ, Insel PA. Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19532-7. Epub 2008 Nov 25. https://doi.org/10.1073/pnas.0806152105
Pekarsky Y, Palamarchuk A, Maximov V, Efanov A, Nazaryan N, Santanam U, Rassenti L, Kipps T, Croce CM. Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL. Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19643-8. Epub 2008 Dec 8. https://doi.org/10.1073/pnas.0810965105

2009

Rieger R, Whitacre D, Cantwell MJ, Prussak C, Kipps TJ. Chimeric form of tumor necrosis factor-alpha has enhanced surface expression and antitumor activity. Cancer Gene Ther. 2009 Jan;16(1):53-64. Epub 2008 Jul 25. https://doi.org/10.1038/cgt.2008.57
O’Brien SM, Claxton DF, Crump M, Faderl S, Kipps T, Keating MJ, Viallet J, Cheson BD. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood. 2009 Jan 8;113(2):299-305. Epub 2008 Oct 17. https://doi.org/10.1182/blood-2008-02-137943
Messmer BT, Raphael BJ, Aerni SJ, Widhopf GF, Rassenti LZ, Gribben JG, Kay NE, Kipps TJ. Computational identification of CDR3 sequence archetypes among immunoglobulin sequences in chronic lymphocytic leukemia. Leuk Res. 2009 Mar;33(3):368-76. Epub 2008 Jul 21. https://doi.org/10.1016/j.leukres.2008.05.022
Lin KI, Tam CS, Keating MJ, Wierda WG, O’Brien S, Lerner S, Coombes KR, Schlette E, Ferrajoli A, Barron LL, Kipps TJ, Rassenti L, Faderl S, Kantarjian H, Abruzzo LV. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. Blood. 2009 Apr 2;113(14):3168-71. Epub 2008 Dec 2. https://doi.org/10.1182/blood-2008-10-184853
Buhl AM, Novotny GW, Josefsson P, Nielsen JE, Pedersen LB, Geisler C, Rassenti LZ, Kipps TJ, Jurlander J, Leffers H. The CLLU1 expression level is a stable and inherent feature of the chronic lymphocytic leukemia clone. Leukemia. 2009 Jun;23(6):1182-6. Epub 2009 Feb 12. https://doi.org/10.1038/leu.2009.16
Steininger C, Rassenti LZ, Vanura K, Eigenberger K, Jäger U, Kipps TJ, Mannhalter C, Stilgenbauer S, Popow-Kraupp T. Relative seroprevalence of human herpes viruses in patients with chronic lymphocytic leukaemia. Eur J Clin Invest. 2009 Jun;39(6):497-506. https://doi.org/10.1111/j.1365-2362.2009.02131.x
Xiao W, Hong H, Kawakami Y, Kato Y, Wu D, Yasudo H, Kimura A, Kubagawa H, Bertoli LF, Davis RS, Chau LA, Madrenas J, Hsia CC, Xenocostas A, Kipps TJ, Hennighausen L, Iwama A, Nakauchi H, Kawakami T. Tumor suppression by phospholipase C-beta3 via SHP-1-mediated dephosphorylation of Stat5. Cancer Cell. 2009 Aug 4;16(2):161-71. https://doi.org/10.1016/j.ccr.2009.05.018
Castro JE, James DF, Sandoval-Sus JD, Jain S, Bole J, Rassenti L, Kipps TJ. Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia. 2009 Oct;23(10):1779-89. Epub 2009 Aug 20. https://doi.org/10.1038/leu.2009.133
Visone R, Rassenti LZ, Veronese A, Taccioli C, Costinean S, Aguda BD, Volinia S, Ferracin M, Palatini J, Balatti V, Alder H, Negrini M, Kipps TJ, Croce CM. Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood. 2009 Oct 29;114(18):3872-9. Epub 2009 Aug 28. h t tps://doi.org/10.1182/blood-2009-06-229211
Enzler T, Kater AP, Zhang W, Widhopf GF 2nd, Chuang HY, Lee J, Avery E, Croce CM, Karin M, Kipps TJ. Chronic lymphocytic leukemia of Eμ-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression. Blood. 2009 Nov 12;114(20):4469-76. Epub 2009 Sep 15. https://doi.org/10.1182/blood-2009-06-230169
Lu D, Liu JX, Endo T, Zhou H, Yao S, Willert K, Schmidt-Wolf IG, Kipps TJ, Carson DA. Ethacrynic acid exhibits selective toxicity to chronic lymphocytic leukemia cells by inhibition of the Wnt/beta-catenin pathway. PLoS One. 2009 Dec 14;4(12):e8294. https://doi.org/10.1371/journal.pone.0008294

2010

Shustik C, Turner AR, Desjardins P, Fernandez L, Rubin S, Larratt L, Duncan AM, Rizi D, Sadura A, Shepherd L, Li D, Rassenti L, Kipps T. Oral fludarabine in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia. 2010 Jan;24(1):237-9. Epub 2009 Oct 8. https://doi.org/10.1038/leu.2009.205
Byrd JC, Kipps TJ, Flinn IW, Castro J, Lin TS, Wierda W, Heerema N, Woodworth J, Hughes S, Tangri S, Harris S, Wynne D, Molina A, Leigh B, O’Brien S. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood. 2010 Jan 21;115(3):489-95. Epub 2009 Oct 20. https://doi.org/10.1182/blood-2009-08-237727
Wojcik SE, Rossi S, Shimizu M, Nicoloso MS, Cimmino A, Alder H, Herlea V, Rassenti LZ, Rai KR, Kipps TJ, Keating MJ, Croce CM, Calin GA. Non-codingRNA sequence variations in human chronic lymphocytic leukemia and colorectal cancer. Carcinogenesis. 2010 Feb;31(2):208-15. Epub 2009 Nov 19. https://doi.org/10.1093/carcin/bgp209
Shi R, Re D, Dudl E, Cuddy M, Okolotowicz KJ, Dahl R, Su Y, Hurder A, Kitada S, Peddibhotla S, Roth GP, Smith LH, Kipps TJ, Cosford N, Cashman J, Reed JC. Chemical biology strategy reveals pathway-selective inhibitor of NF-kappaB activation induced by protein kinase C. ACS Chem Biol. 2010 Mar 19;5(3):287-99. https://doi.org/10.1021/cb9003089
Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillmen P, Trneny M, Dyer MJ, Padmanabhan S, Piotrowska M, Kozak T, Chan G, Davis R, Losic N, Wilms J, Russell CA, Osterborg A; Hx-CD20-406 Study Investigators. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010 Apr 1;28(10):1749-55. Epub 2010 Mar 1. https://doi.org/10.1200/JCO.2009.25.3187
Du S, Rashidi HH, Le DT, Kipps TJ, Broome HE, Wang HY. Systemic mastocytosis in association with chronic lymphocytic leukemia and plasma cell myeloma. Int J Clin Exp Pathol. 2010 Apr 23;3(4):448-57. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2872752/
Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, Drusco A, Marchesini J, Mascellani N, Sana ME, Abu Jarour R, Desponts C, Teitell M, Baffa R, Aqeilan R, Iorio MV, Taccioli C, Garzon R, Di Leva G, Fabbri M, Catozzi M, Previati M, Ambs S, Palumbo T, Garofalo M, Veronese A, Bottoni A, Gasparini P, Harris CC, Visone R, Pekarsky Y, de la Chapelle A, Bloomston M, Dillhoff M, Rassenti LZ, Kipps TJ, Huebner K, Pichiorri F, Lenze D, Cairo S, Buendia MA, Pineau P, Dejean A, Zanesi N, Rossi S, Calin GA, Liu CG, Palatini J, Negrini M, Vecchione A, Rosenberg A, Croce CM. Reprogramming of miRNA networks in cancer and leukemia. Genome Res. 2010 May;20(5):589-99. https://doi.org/10.1101/gr.098046.109
Palamarchuk A, Efanov A, Nazaryan N, Santanam U, Alder H, Rassenti L, Kipps T, Croce CM, Pekarsky Y. 13q14 deletions in CLL involve cooperating tumor suppressors. Blood. 2010 May 13;115(19):3916-22. Epub 2010 Jan 13. https://doi.org/10.1182/blood-2009-10-249367
Haferlach T, Kohlmann A, Wieczorek L, Basso G, Kronnie GT, Béné MC, De Vos J, Hernández JM, Hofmann WK, Mills KI, Gilkes A, Chiaretti S, Shurtleff SA, Kipps TJ, Rassenti LZ, Yeoh AE, Papenhausen PR, Liu WM, Williams PM, Foà R. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol. 2010 May 20;28(15):2529-37. Epub 2010 Apr 20. https://doi.org/10.1200/JCO.2009.23.4732
Santanam U, Zanesi N, Efanov A, Costinean S, Palamarchuk A, Hagan JP, Volinia S, Alder H, Rassenti L, Kipps T, Croce CM, Pekarsky Y. Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. Proc Natl Acad Sci U S A. 2010 Jul 6;107(27):12210-5. Epub 2010 Jun 21. https://doi.org/10.1073/pnas.1007186107
O’Hayre M, Salanga CL, Kipps TJ, Messmer D, Dorrestein PC, Handel TM. Elucidating the CXCL12/CXCR4 signaling network in chronic lymphocytic leukemia through phosphoproteomics analysis. PLoS One. 2010 Jul 22;5(7):e11716. https://doi.org/10.1371/journal.pone.0011716
Chanan-Khan A, Kipps T, Stilgenbauer S. New alternatives in CLL therapy: managing adverse events. Clin Adv Hematol Oncol. 2010 Aug;8(8):suppl 1-15. https://www.hematologyandoncology.net/supplements/new-alternatives-in-cll-therapy-managing-adverse-events/
Rossi S, Shimizu M, Barbarotto E, Nicoloso MS, Dimitri F, Sampath D, Fabbri M, Lerner S, Barron LL, Rassenti LZ, Jiang L, Xiao L, Hu J, Secchiero P, Zauli G, Volinia S, Negrini M, Wierda W, Kipps TJ, Plunkett W, Coombes KR, Abruzzo LV, Keating MJ, Calin GA. microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood. 2010 Aug 12;116(6):945-52. Epub 2010 Apr 14. https://doi.org/10.1182/blood-2010-01-263889
Sanchez AB, Nguyen T, Dema-Ala R, Kummel AC, Kipps TJ, Messmer BT. A general process for the development of peptide-based immunoassays for monoclonal antibodies. Cancer Chemother Pharmacol. 2010 Oct;66(5):919-25. Epub 2010 Jan 20. https://doi.org/10.1007/s00280-009-1240-1
Setlur SR, Ihm C, Tchinda J, Shams S, Werner L, Cho EK, Thompson C, Phillips K, Rassenti LZ, Kipps TJ, Neuberg D, Freedman AS, Lee C, Brown JR. Comparison of familial and sporadic chronic lymphocytic leukaemia using high resolution array comparative genomic hybridization. Br J Haematol. 2010 Nov;151(4):336-45. Epub 2010 Aug 31. https://doi.org/10.1111/j.1365-2141.2010.08341.x
Wierda WG, Castro JE, Aguillon R, Sampath D, Jalayer A, McMannis J, Prussak CE, Keating M, Kipps TJ. A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154. Leukemia. 2010 Nov;24(11):1893-900. Epub 2010 Sep 30. https://doi.org/10.1038/leu.2010.191
Zhang W, Kater AP, Widhopf GF 2nd, Chuang HY, Enzler T, James DF, Poustovoitov M, Tseng PH, Janz S, Hoh C, Herschman H, Karin M, Kipps TJ. B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18956-60. Epub 2010 Oct 18. https://doi.org/10.1073/pnas.1013420107
Heerema NA, Byrd JC, Dal Cin PS, Dell’ Aquila ML, Koduru PR, Aviram A, Smoley SA, Rassenti LZ, Greaves AW, Brown JR, Rai KR, Kipps TJ, Kay NE, Van Dyke DL; Chronic Lymphocytic Leukemia Research Consortium. Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) Study. Cancer Genet Cytogenet. 2010 Dec;203(2):134-40. https://doi.org/10.1016/j.cancergencyto.2010.07.128
Smoley SA, Van Dyke DL, Kay NE, Heerema NA, Dell’ Aquila ML, Dal Cin P, Koduru P, Aviram A, Rassenti L, Byrd JC, Rai KR, Brown JR, Greaves AW, Eckel-Passow J, Neuberg D, Kipps TJ, Dewald GW. Standardization of fluorescence in situ hybridization studies on chronic lymphocytic leukemia (CLL) blood and marrow cells by the CLL Research Consortium. Cancer Genet Cytogenet. 2010 Dec;203(2):141-8. https://doi.org/10.1016/j.cancergencyto.2010.08.009
Kay NE, Eckel-Passow JE, Braggio E, Vanwier S, Shanafelt TD, Van Dyke DL, Jelinek DF, Tschumper RC, Kipps T, Byrd JC, Fonseca R. Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy. Cancer Genet Cytogenet. 2010 Dec;203(2):161-8. https://doi.org/10.1016/j.cancergencyto.2010.09.003

2011

Wierda WG, Kipps TJ, Keating MJ, Brown JR, Gribben JG, Browning M, Rassenti LZ, Greaves AW, Neuberg D, O’Brien SM; CLL Research Consortium. Self- administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. Cancer. 2011 Jan 1;117(1):116-24. Epub 2010 Aug 30. https://doi.org/10.1002/cncr.25379
Fabbri M, Bottoni A, Shimizu M, Spizzo R, Nicoloso MS, Rossi S, Barbarotto E, Cimmino A, Adair B, Wojcik SE, Valeri N, Calore F, Sampath D, Fanini F, Vannini I, Musuraca G, Dell’Aquila M, Alder H, Davuluri RV, Rassenti LZ, Negrini M, Nakamura T, Amadori D, Kay NE, Rai KR, Keating MJ, Kipps TJ, Calin GA, Croce CM. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA. 2011 Jan 5;305(1):59-67. https://doi.org/10.1001/jama.2010.1919
Messmer D, Fecteau JF, O’Hayre M, Bharati IS, Handel TM, Kipps TJ. Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib. Blood. 2011 Jan 20;117(3):882-9. Epub 2010 Nov 15. https://doi.org/10.1182/blood-2010-04-282400
Sivina M, Hartmann E, Kipps TJ, Rassenti L, Krupnik D, Lerner S, LaPushin R, Xiao L, Huang X, Werner L, Neuberg D, Kantarjian H, O’Brien S, Wierda WG, Keating MJ, Rosenwald A, Burger JA. CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood. 2011 Feb 3;117(5):1662-9. Epub 2010 Nov 29. https://doi.org/10.1182/blood-2010-09-307249
Buhl AM, James DF, Neuberg D, Jain S, Rassenti LZ, Kipps TJ. Analysis of CLLU1 expression levels before and after therapy in patients with chronic lymphocytic leukemia. Eur J Haematol. 2011 May;86(5):405-411. Epub 2011 Mar 23. https://doi.org/10.1111/j.1600-0609.2011.01588.x
Vandewoestyne ML, Pede VC, Lambein KY, Dhaenens MF, Offner FC, Praet MM, Philippé JJ, Kipps TJ, Deforce DL. Laser microdissection for the assessment of the clonal relationship between chronic lymphocytic leukemia/small lymphocytic lymphoma and proliferating B cells within lymph node pseudofollicles. Leukemia. 2011 May;25(5):883-8. Epub 2011 Feb 15. https://doi.org/10.1038/leu.2011.14
Ghia EM, Widhopf GF 2nd, Rassenti LZ, Kipps TJ. Analyses of recombinant stereotypic IGHV3-21-encoded antibodies expressed in chronic lymphocytic leukemia. J Immunol. 2011 Jun 1;186(11):6338-44. Epub 2011 Apr 27. https://doi.org/10.4049/jimmunol.0902875
Wierda WG, Kipps TJ, Dürig J, Griskevicius L, Stilgenbauer S, Mayer J, Smolej L, Hess G, Griniute R, Hernandez-Ilizaliturri FJ, Padmanabhan S, Gorczyca M, Chang CN, Chan G, Gupta I, Nielsen TG, Russell CA; 407 Study Investigators. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood. 2011 Jun 16;117(24):6450-8. Epub 2011 Apr 15. https://doi.org/10.1182/blood-2010-12-323980
James DF, Kipps TJ. Rituximab in chronic lymphocytic leukemia. Adv Ther. 2011 Jul;28(7):534-54. Epub 2011 Jul 2. https://doi.org/10.1007/s12325-011-0032-2
Messmer BT, Nour-Omid TS, Ghia E, Sanchez AB, Kipps TJ. Autoantibodies against p53 are associated with chromosome 17p deletions in chronic lymphocytic leukemia. Leuk Res. 2011 Jul;35(7):965-7. Epub 2011 May 12. https://doi.org/10.1016/j.leukres.2011.04.009
Lu D, Choi MY, Yu J, Castro JE, Kipps TJ, Carson DA. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A. 2011 Aug 9;108(32):13253-7. Epub 2011 Jul 25. https://doi.org/10.1073/pnas.1110431108
Peiró AM, Tang CM, Murray F, Zhang L, Brown LM, Chou D, Rassenti L, Kipps TJ, Insel PA. Genetic variation in phosphodiesterase (PDE) 7B in chronic lymphocytic leukemia: overview of genetic variants of cyclic nucleotide PDEs in human disease. J Hum Genet. 2011 Sep;56(9):676-81. Epub 2011 Jul 28. https://doi.org/10.1038/jhg.2011.80
Zhang L, Murray F, Rassenti LZ, Pu M, Kelly C, Kanter JR, Greaves A, Messer K, Kipps TJ, Insel PA. Cyclic nucleotide phosphodiesterase 7B mRNA: an unfavorable characteristic in chronic lymphocytic leukemia. Int J Cancer. 2011 Sep 1;129(5):1162-9. Epub 2011 Feb 11. https://doi.org/10.1002/ijc.25785
Havelange V, Pekarsky Y, Nakamura T, Palamarchuk A, Alder H, Rassenti L, Kipps T, Croce CM. IRF4 mutations in chronic lymphocytic leukemia. Blood. 2011 Sep 8;118(10):2827-9. Epub 2011 Jul 25. https://doi.org/10.1182/blood-2011-04-350579
Visone R, Veronese A, Rassenti LZ, Balatti V, Pearl DK, Acunzo M, Volinia S, Taccioli C, Kipps TJ, Croce CM. miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia. Blood. 2011 Sep 15;118(11):3072-9. Epub 2011 Jun 2. https://doi.org/10.1182/blood-2011-01-333484
Broome HE, Rassenti LZ, Wang HY, Meyer LM, Kipps TJ. ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia. Leuk Res. 2011 Oct;35(10):1390-4. Epub 2011 Aug 2. https://doi.org/10.1016/j.leukres.2011.06.021

2012

Fecteau JF, Kipps TJ. Structure and function of the hematopoietic cancer niche: focus on chronic lymphocytic leukemia. Front Biosci (Schol Ed). 2012 Jan 1;4:61-73. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4114230/
Gaudio E, Spizzo R, Paduano F, Luo Z, Efanov A, Palamarchuk A, Leber AS, Kaou M, Zanesi N, Bottoni A, Costinean S, Rassenti LZ, Nakamura T, Kipps TJ, Aqeilan RI, Pekarsky Y, Trapasso F, Croce CM. Tcl1 interacts with Atm and enhances NF-κB activation in hematologic malignancies. Blood. 2012 Jan 5;119(1):180-7. Epub 2011 Nov 7. https://doi.org/10.1182/blood-2011-08-374561
Balatti V, Bottoni A, Palamarchuk A, Alder H, Rassenti LZ, Kipps TJ, Pekarsky Y, Croce CM. NOTCH1 mutations in CLL associated with trisomy 12. Blood. 2012 Jan 12;119(2):329-31. Epub 2011 Nov 15. https://doi.org/10.1182/blood-2011-10-386144
Fecteau JF, Bharati IS, O’Hayre M, Handel TM, Kipps TJ, Messmer D. Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1). Mol Med. 2012 Feb 10;18(1):19-28. https://doi.org/10.2119/molmed.2011.00164
Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, Carney DA, He SZ, Huang DC, Xiong H, Cui Y, Busman TA, McKeegan EM, Krivoshik AP, Enschede SH, Humerickhouse R. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012 Feb 10;30(5):488-96. Epub 2011 Dec 19. https://doi.org/10.1200/JCO.2011.34.7898
Palamarchuk A, Yan PS, Zanesi N, Wang L, Rodrigues B, Murphy M, Balatti V, Bottoni A, Nazaryan N, Alder H, Rassenti L, Kipps TJ, Freitas M, Croce CM, Pekarsky Y. Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL). Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2555-60. Epub 2012 Jan 30. https://doi.org/10.1073/pnas.1200003109
Zhang S, Chen L, Cui B, Chuang HY, Yu J, Wang-Rodriguez J, Tang L, Chen G, Basak GW, Kipps TJ. ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. PLoS One. 2012 Mar 5;7(3):e31127. https://doi.org/10.1371/journal.pone.0031127
Steininger C, Widhopf GF 2nd, Ghia EM, Morello CS, Vanura K, Sanders R, Spector D, Guiney D, Jäger U, Kipps TJ. Recombinant antibodies encoded by IGHV1-69 react with pUL32, a phosphoprotein of cytomegalovirus and B-cell superantigen. Blood. 2012 Mar 8;119(10):2293-301. Epub 2012 Jan 10. https://doi.org/10.1182/blood-2011-08-374058
Melo-Cardenas J, Urquiza M, Kipps TJ, Castro JE. Intratumoral delivery of CD154 homolog (Ad-ISF35) induces tumor regression: analysis of vector biodistribution, persistence and gene expression. Cancer Gene Ther. 2012 May;19(5):336-44. Epub 2012 Mar 9. https://doi.org/10.1038/cgt.2012.6
Castro JE, Melo-Cardenas J, Urquiza M, Barajas-Gamboa JS, Pakbaz RS, Kipps TJ. Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule. Cancer Res. 2012 Jun 15;72(12):2937-48. Epub 2012 Apr 13. https://doi.org/10.1158/0008-5472.CAN-11-3368
O’Hayre M, Niederst M, Fecteau JF, Nguyen VM, Kipps TJ, Messmer D, Newton AC, Handel TM. Mechanisms and consequences of the loss of PHLPP1 phosphatase in chronic lymphocytic leukemia (CLL). Leukemia. 2012 Jul;26(7):1689-92. Epub 2012 Jan 12. https://doi.org/10.1038/leu.2012.6
Claus R, Lucas DM, Stilgenbauer S, Ruppert AS, Yu L, Zucknick M, Mertens D, Bühler A, Oakes CC, Larson RA, Kay NE, Jelinek DF, Kipps TJ, Rassenti LZ, Gribben JG, Döhner H, Heerema NA, Marcucci G, Plass C, Byrd JC. Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. J Clin Oncol. 2012 Jul 10;30(20):2483-91. Epub 2012 May 7. https://doi.org/10.1200/JCO.2011.39.3090
Cheson BD, Byrd JC, Rai KR, Kay NE, O’Brien SM, Flinn IW, Wiestner A, Kipps TJ. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol. 2012 Aug 10;30(23):2820-2. Epub 2012 Jul 9. https://doi.org/10.1200/JCO.2012.43.3748
Coombs CC, Rassenti LZ, Falchi L, Slager SL, Strom SS, Ferrajoli A, Weinberg JB, Kipps TJ, Lanasa MC. Single nucleotide polymorphisms and inherited risk of chronic lymphocytic leukemia among African Americans. Blood. 2012 Aug 23;120(8):1687-90. Epub 2012 Jun 28. https://doi.org/10.1182/blood-2012-02-408799
Castro JE, Diaz-Perez JA, Barajas-Gamboa JS, Horton JM, Weidner N, Kipps TJ. Chronic lymphocytic leukemia associated with immunotactoid glomerulopathy: a case report of successful treatment with high-dose methylprednisolone in combination with rituximab followed by alemtuzumab. Leuk Lymphoma. 2012 Sep;53(9):1835-8. Epub 2012 Mar 13. https://doi.org/10.3109/10428194.2012.663914
Tili E, Michaille JJ, Luo Z, Volinia S, Rassenti LZ, Kipps TJ, Croce CM. The down-regulation of miR-125b in chronic lymphocytic leukemias leads to metabolic adaptation of cells to a transformed state. Blood. 2012 Sep 27;120(13):2631-8. Epub 2012 Jun 21. https://doi.org/10.1182/blood-2012-03-415737
Chuang HY, Rassenti L, Salcedo M, Licon K, Kohlmann A, Haferlach T, Foà R, Ideker T, Kipps TJ. Subnetwork-based analysis of chronic lymphocytic leukemia identifies pathways that associate with disease progression. Blood. 2012 Sep 27;120(13):2639-49. Epub 2012 Jul 26. https://doi.org/10.1182/blood-2012-03-416461
Choi MY, Kipps TJ. Inhibitors of B-cell receptor signaling for patients with B-cell malignancies. Cancer J. 2012 Sep-Oct;18(5):404-10. https://doi.org/10.1097/PPO.0b013e31826c5810
Byrd JC, Kipps TJ, Flinn IW, Cooper M, Odenike O, Bendiske J, Rediske J, Bilic S, Dey J, Baeck J, O’Brien S. Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. Leuk Lymphoma. 2012 Nov;53(11):2136-42. Epub 2012 Jun 12. https://doi.org/10.3109/10428194.2012.681655
Zhang S, Chen L, Wang-Rodriguez J, Zhang L, Cui B, Frankel W, Wu R, Kipps TJ. The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. Am J Pathol. 2012 Dec;181(6):1903-10. Epub 2012 Oct 4. https://doi.org/10.1016/j.ajpath.2012.08.024

2013

Gaudio E, Paduano F, Ngankeu A, Lovat F, Fabbri M, Sun HL, Gasparini P, Efanov A, Peng Y, Zanesi N, Shuaib MA, Rassenti LZ, Kipps TJ, Li C, Aqeilan RI, Lesinski GB, Trapasso F, Croce CM. Heat shock protein 70 regulates Tcl1 expression in leukemia and lymphomas. Blood. 2013 Jan 10;121(2):351-9. Epub 2012 Nov 15. https://doi.org/10.1182/blood-2012-09-457374
Wu RP, Li H, Rassenti LZ, Hayashi T, Wu CN, Kipps TJ, Messer K, Carson DA. Increased aldehyde dehydrogenase activity in high-risk chronic lymphocytic leukemia. Leuk Lymphoma. 2013 Feb;54(2):400-2. Epub 2012 Aug 13. https://doi.org/10.3109/10428194.2012.709630
Fecteau JF, Messmer D, Zhang S, Cui B, Chen L, Kipps TJ. Impact of oxygen concentration on growth of mesenchymal stromal cells from the marrow of patients with chronic lymphocytic leukemia. Blood. 2013 Feb 7;121(6):971-4. Epub 2012 Dec 18. https://doi.org/10.1182/blood-2012-08-447813
Balatti V, Lerner S, Rizzotto L, Rassenti LZ, Bottoni A, Palamarchuk A, Cascione L, Alder H, Keating MJ, Kipps TJ, Pekarsky Y, Croce CM. Trisomy 12 CLLs progress through NOTCH1 mutations. Leukemia. 2013 Mar;27(3):740-3. Epub 2012 Aug 20. https://doi.org/10.1038/leu.2012.239
Schwaederlé M, Ghia E, Rassenti LZ, Obara M, Dell’Aquila ML, Fecteau JF, Kipps TJ. Subclonal evolution involving SF3B1 mutations in chronic lymphocytic leukemia. Leukemia. 2013 Apr;27(5):1214-7. Epub 2013 Jan 22. https://doi.org/10.1038/leu.2013.22
Sonnenberg A, Marciniak JY, McCanna J, Krishnan R, Rassenti L, Kipps TJ, Heller MJ. Dielectrophoretic isolation and detection of cfc-DNA nanoparticulate biomarkers and virus from blood. Electrophoresis. 2013 Apr;34(7):1076-84. https://doi.org/10.1002/elps.201200444
Zhang S, Wu CC, Fecteau JF, Cui B, Chen L, Zhang L, Wu R, Rassenti L, Lao F, Weigand S, Kipps TJ. Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44. Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6127-32. Epub 2013 Mar 25. https://doi.org/10.1073/pnas.1221841110
Brown JR, Messmer B, Werner L, Davids MS, Mikler E, Supko JG, Fisher DC, LaCasce AS, Armand P, Jacobsen E, Dalton V, Tesar B, Fernandes SM, McDonough S, Ritz J, Rassenti L, Kipps TJ, Neuberg D, Freedman AS. A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Haematologica. 2013 Jun;98(6):964-70. Epub 2013 May 3. https://doi.org/10.3324/haematol.2013.086207
Cui B, Zhang S, Chen L, Yu J, Widhopf GF 2nd, Fecteau JF, Rassenti LZ, Kipps TJ. Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis. Cancer Res. 2013 Jun 15;73(12):3649-60. https://doi.org/10.1158/0008-5472.CAN-12-3832
Que X, Widhopf GF 2nd, Amir S, Hartvigsen K, Hansen LF, Woelkers D, Tsimikas S, Binder CJ, Kipps TJ, Witztum JL. IGHV1-69-encoded antibodies expressed in chronic lymphocytic leukemia react with malondialdehyde-acetaldehyde adduct, an immunodominant oxidation-specific epitope. PLoS One. 2013 Jun 20;8(6):e65203. https://doi.org/10.1371/journal.pone.0065203
Mraz M, Kipps TJ. MicroRNAs and B cell receptor signaling in chronic lymphocytic leukemia. Leuk Lymphoma. 2013 Aug;54(8):1836-9. Epub 2013 Jun 12. https://doi.org/10.3109/10428194.2013.796055
Ferrajoli A, Shanafelt TD, Ivan C, Shimizu M, Rabe KG, Nouraee N, Ikuo M, Ghosh AK, Lerner S, Rassenti LZ, Xiao L, Hu J, Reuben JM, Calin S, You MJ, Manning JT, Wierda WG, Estrov Z, O’Brien S, Kipps TJ, Keating MJ, Kay NE, Calin GA. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood. 2013 Sep 12;122(11):1891-9. Epub 2013 Jul 2. https://doi.org/10.1182/blood-2013-01-478222
Villa R, Kashyap MK, Kumar D, Kipps TJ, Castro JE, La Clair JJ, Burkart MD. Stabilized cyclopropane analogs of the splicing inhibitor FD-895. J Med Chem. 2013 Sep 12;56(17):6576-82. Epub 2013 Aug 21. https://doi.org/10.1021/jm400861t
Tsimberidou AM, Wierda WG, Wen S, Plunkett W, O’Brien S, Kipps TJ, Jones JA, Badoux X, Kantarjian H, Keating MJ; Chronic Lymphocytic Leukemia Research Consortium. Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome. Clin Lymphoma Myeloma Leuk. 2013 Oct;13(5):568-74. Epub 2013 Jun 27. https://doi.org/10.1016/j.clml.2013.03.012
Lascano V, Guadagnoli M, Schot JG, Luijks DM, Guikema JE, Cameron K, Hahne M, Pals S, Slinger E, Kipps TJ, van Oers MH, Eldering E, Medema JP, Kater AP. Chronic lymphocytic leukemia disease progression is accelerated by APRIL-TACI interaction in the TCL1 transgenic mouse model. Blood. 2013 Dec 5;122(24):3960-3. Epub 2013 Oct 7. https://doi.org/10.1182/blood-2013-04-497693

2014

Zhang S, Kipps TJ. The pathogenesis of chronic lymphocytic leukemia. Annu Rev Pathol. 2014;9:103-18. Epub 2013 Aug 26. https://doi.org/10.1146/annurev-pathol-020712-163955
Widhopf GF 2nd, Cui B, Ghia EM, Chen L, Messer K, Shen Z, Briggs SP, Croce CM, Kipps TJ. ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice. Proc Natl Acad Sci U S A. 2014 Jan 14;111(2):793-8. Epub 2013 Dec 30. https://doi.org/10.1073/pnas.1308374111
Oakes CC, Claus R, Gu L, Assenov Y, Hüllein J, Zucknick M, Bieg M, Brocks D, Bogatyrova O, Schmidt CR, Rassenti L, Kipps TJ, Mertens D, Lichter P, Döhner H, Stilgenbauer S, Byrd JC, Zenz T, Plass C. Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia. Cancer Discov. 2014 Mar;4(3):348-61. Epub 2013 Dec 19. https://doi.org/10.1158/2159-8290.CD-13-0349
Sonnenberg A, Marciniak JY, Rassenti L, Ghia EM, Skowronski EA, Manouchehri S, McCanna J, Widhopf GF 2nd, Kipps TJ, Heller MJ. Rapid electrokinetic isolation of cancer-related circulating cell-free DNA directly from blood. Clin Chem. 2014 Mar;60(3):500-9. Epub 2013 Nov 22. https://doi.org/10.1373/clinchem.2013.214874
Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Stilgenbauer S, Cramer P, Aiello M, Johnson DM, Miller LL, Li D, Jahn TM, Dansey RD, Hallek M, O’Brien SM. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014 Mar 13;370(11):997-1007. Epub 2014 Jan 22. https://doi.org/10.1056/NEJMoa1315226
Woyach JA, Smucker K, Smith LL, Lozanski A, Zhong Y, Ruppert AS, Lucas D, Williams K, Zhao W, Rassenti L, Ghia E, Kipps TJ, Mantel R, Jones J, Flynn J, Maddocks K, O’Brien S, Furman RR, James DF, Clow F, Lozanski G, Johnson AJ, Byrd JC. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014 Mar 20;123(12):1810-7. Epub 2014 Jan 10. https://doi.org/10.1182/blood-2013-09-527853
Glibert P, Vossaert L, Van Steendam K, Lambrecht S, Van Nieuwerburgh F, Offner F, Kipps T, Dhaenens M, Deforce D. Quantitative proteomics to characterize specific histone H2A proteolysis in chronic lymphocytic leukemia and the myeloid THP-1 cell line. Int J Mol Sci. 2014 May 27;15(6):9407-21. https://doi.org/10.3390/ijms15069407
Riches JC, O’Donovan CJ, Kingdon SJ, McClanahan F, Clear AJ, Neuberg DS, Werner L, Croce CM, Ramsay AG, Rassenti LZ, Kipps TJ, Gribben JG. Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations. Blood. 2014 Jun 26;123(26):4101-10. Epub 2014 May 14. https://doi.org/10.1182/blood-2014-01-552307
Sonnenberg A, Marciniak JY, Skowronski EA, Manouchehri S, Rassenti L, Ghia EM, Widhopf GF 2nd, Kipps TJ, Heller MJ. Dielectrophoretic isolation and detection of cancer-related circulating cell-free DNA biomarkers from blood and plasma. Electrophoresis. 2014 Jul;35(12-13):1828-36. Epub 2014 May 14. https://doi.org/10.1002/elps.201400016
Claus R, Lucas DM, Ruppert AS, Williams KE, Weng D, Patterson K, Zucknick M, Oakes CC, Rassenti LZ, Greaves AW, Geyer S, Wierda WG, Brown JR, Gribben JG, Barrientos JC, Rai KR, Kay NE, Kipps TJ, Shields P, Zhao W, Grever MR, Plass C, Byrd JC. Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia. Blood. 2014 Jul 3;124(1):42-8. Epub 2014 May 27. https://doi.org/10.1182/blood-2014-02-555722
Mraz M, Chen L, Rassenti LZ, Ghia EM, Li H, Jepsen K, Smith EN, Messer K, Frazer KA, Kipps TJ. miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1. Blood. 2014 Jul 3;124(1):84-95. Epub 2014 May 1. https://doi.org/10.1182/blood-2013-09-527234
James DF, Werner L, Brown JR, Wierda WG, Barrientos JC, Castro JE, Greaves A, Johnson AJ, Rassenti LZ, Rai KR, Neuberg D, Kipps TJ. Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium. J Clin Oncol. 2014 Jul 1;32(19):2067-73. Epub 2014 May 27. https://doi.org/10.1200/JCO.2013.51.5890
Acunzo M, Romano G, Wernicke D, Balatti V, Rassenti LZ, dell’Aquila M, Kipps TJ, Pekarsky Y, Croce CM. Translocation t(2;11) in CLL cells results in CXCR4/MAML2 fusion oncogene. Blood. 2014 Jul 10;124(2):259-62. Epub 2014 May 22. https://doi.org/10.1182/blood-2014-02-554675
Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P; RESONATE Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014 Jul 17;371(3):213-23. Epub 2014 May 31. https://doi.org/10.1056/NEJMoa1400376
Cui B, Chen L, Zhang S, Mraz M, Fecteau JF, Yu J, Ghia EM, Zhang L, Bao L, Rassenti LZ, Messer K, Calin GA, Croce CM, Kipps TJ. MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood. 2014 Jul 24;124(4):546-54. Epub 2014 Jun 9. https://doi.org/10.1182/blood-2014-03-559690
Smith EN, Jepsen K, Khosroheidari M, Rassenti LZ, D’Antonio M, Ghia EM, Carson DA, Jamieson CH, Kipps TJ, Frazer KA. Biased estimates of clonal evolution and subclonal heterogeneity can arise from PCR duplicates in deep sequencing experiments. Genome Biol. 2014 Aug 7;15(8):420. https://doi.org/10.1186/s13059-014-0420-4
Fecteau JF, Corral LG, Ghia EM, Gaidarova S, Futalan D, Bharati IS, Cathers B, Schwaederlé M, Cui B, Lopez-Girona A, Messmer D, Kipps TJ. Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21^WAF1/Cip1-dependent mechanism independent of functional p53. Blood. 2014 Sep 4;124(10):1637-44. Epub 2014 Jul 2. https://doi.org/10.1182/blood-2014-03-559591
Castro JE, Choi MY, Carvajal T, Almahasnah E, Chang J, James DF, Kipps TJ. Ofatumumab and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia. Blood Cancer J. 2014 Nov 14;4(11):e258. https://doi.org/10.1038/bcj.2014.76
Zhang S, Cui B, Lai H, Liu G, Ghia EM, Widhopf GF 2nd, Zhang Z, Wu CC, Chen L, Wu R, Schwab R, Carson DA, Kipps TJ. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy. Proc Natl Acad Sci U S A. 2014 Dec 2;111(48):17266-71. Epub 2014 Nov 19. https://doi.org/10.1073/pnas.1419599111
Rawstron A, Fazi C, Villamor N, Delgado J, Letestu R, Cymbalista F, Palacio C, Bosch F, De Tute RM, Liptrot S, O’Brien D, Spacek M, Dobber J, Kater AP, Gambell PC, Westerman DA, Soosapilla A, Mulligan SP, Lozanski G, Lin K, Pettitt AR, Brachtl G, Egle A, Williamson DW, Sanders CM, Robins H, Boysen J, Shanafelt TD, Hanson CA, Jorgensen JL, Wierda WG, Yuan C, Stetler-Stevenson M, Rassenti L, Broome HE, Kipps TJ, Hauwel M, Marinov I, Craig FE, Josep N, Moreno C, Stehlikova O, Doubek M, Pospisilova S, Kreuzer KA, Hallek M, Hillmen P, Montserrat E, Ghia P. A complementary role of high throughput sequencing and multiparameter cytometry for minimal residual disease (MRD) detection in chronic lymphocytic leukemia (CLL): an European Research Initiative (ERIC) study. Blood. 2014 Dec 6;124(21):1976-1976. https://doi.org/10.1182/blood.V124.21.1976.1976

2015

Urquiza M, Melo-Cardenas J, Aguillon R, Kipps TJ, Castro JE. Intratumoral injection of Ad-ISF35 (Chimeric CD154) breaks tolerance and induces lymphoma tumor regression. Hum Gene Ther. 2015 Jan;26(1):14-25. https://doi.org/10.1089/hum.2014.015
Veronese A, Pepe F, Chiacchia J, Pagotto S, Lanuti P, Veschi S, Di Marco M, D’Argenio A, Innocenti I, Vannata B, Autore F, Marchisio M, Wernicke D, Verginelli F, Leone G, Rassenti LZ, Kipps TJ, Mariani-Costantini R, Laurenti L, Croce CM, Visone R. Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia. Version 2. Leukemia. 2015 Jan;29(1):86-95. Epub 2014 Apr 15. https://doi.org/10.1038/leu.2014.139
Kämpjärvi K, Järvinen TM, Heikkinen T, Ruppert AS, Senter L, Hoag KW, Dufva O, Kontro M, Rassenti L, Hertlein E, Kipps TJ, Porkka K, Byrd JC, de la Chapelle A, Vahteristo P. Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia. Oncotarget. 2015 Jan 30;6(3):1884-8. https://doi.org/10.18632/oncotarget.2753
Balatti V, Rizzotto L, Miller C, Palamarchuk A, Fadda P, Pandolfo R, Rassenti LZ, Hertlein E, Ruppert AS, Lozanski A, Lozanski G, Kipps TJ, Byrd JC, Croce CM, Pekarsky Y. TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2015 Feb 17;112(7):2169-74. Epub 2015 Feb 2. https://doi.org/10.1073/pnas.1500010112
DeBoever C, Ghia EM, Shepard PJ, Rassenti L, Barrett CL, Jepsen K, Jamieson CH, Carson D, Kipps TJ, Frazer KA. Transcriptome sequencing reveals potential mechanism of cryptic 3′ splice site selection in SF3B1-mutated cancers. PLoS Comput Biol. 2015 Mar 13;11(3):e1004105. https://doi.org/10.1371/journal.pcbi.1004105
Blachly JS, Ruppert AS, Zhao W, Long S, Flynn J, Flinn I, Jones J, Maddocks K, Andritsos L, Ghia EM, Rassenti LZ, Kipps TJ, de la Chapelle A, Byrd JC. Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2015 Apr 7;112(14):4322-7. Epub 2015 Mar 18. https://doi.org/10.1073/pnas.1503587112
Smith EN, Ghia EM, DeBoever CM, Rassenti LZ, Jepsen K, Yoon KA, Matsui H, Rozenzhak S, Alakus H, Shepard PJ, Dai Y, Khosroheidari M, Bina M, Gunderson KL, Messer K, Muthuswamy L, Hudson TJ, Harismendy O, Barrett CL, Jamieson CH, Carson DA, Kipps TJ, Frazer KA. Genetic and epigenetic profiling of CLL disease progression reveals limited somatic evolution and suggests a relationship to memory-cell development. Blood Cancer J. 2015 Apr 10;5(4):e303. https://doi.org/10.1038/bcj.2015.14
Ferrajoli A, Ivan C, Ciccone M, Shimizu M, Kita Y, Ohtsuka M, D’Abundo L, Qiang J, Lerner S, Nouraee N, Rabe KG, Rassenti LZ, Van Roosbroeck K, Manning JT, Yuan Y, Zhang X, Shanafelt TD, Wierda WG, Sabbioni S, Tarrand JJ, Estrov Z, Radovich M, Liang H, Negrini M, Kipps TJ, Kay NE, Keating M, Calin GA. Epstein-Barr virus microRNAs are expressed in patients with chronic lymphocytic leukemia and correlate with overall survival. EBioMedicine. 2015 Apr 29;2(6):572-82. https://doi.org/10.1016/j.ebiom.2015.04.018
Brown JR, O’Brien S, Kingsley CD, Eradat H, Pagel JM, Lymp J, Hirata J, Kipps TJ. Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial. Blood. 2015 Apr 30;125(18):2779-85. Epub 2015 Mar 13. https://doi.org/10.1182/blood-2014-12-613570
Lanasa MC, Andritsos L, Brown JR, Gabrilove J, Caligaris-Cappio F, Ghia P, Larson RA, Kipps TJ, Leblond V, Milligan DW, Janssens A, Johnson AJ, Heerema NA, Bühler A, Stilgenbauer S, Devin J, Hallek M, Byrd JC, Grever MR. Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia. Leuk Res. 2015 May;39(5):495-500. Epub 2015 Feb 7. https://doi.org/10.1016/j.leukres.2015.02.001
Choi MY, Widhopf GF 2nd, Wu CC, Cui B, Lao F, Sadarangani A, Cavagnaro J, Prussak C, Carson DA, Jamieson C, Kipps TJ. Pre-clinical specificity and safety of UC-961, a first-in-class monoclonal antibody targeting ROR1. Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl(0):S167-9. https://doi.org/10.1016/j.clml.2015.02.010
Strati P, Tong WG, Vitale C, Wierda WG, O’Brien S, Brown JR, Weng WK, Kipps T, Keating MJ, Ferrajoli A. A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2015 Jun;56(6):1878-80. Epub 2014 Nov 20. https://doi.org/10.3109/10428194.2014.974049
Deniger DC, Yu J, Huls MH, Figliola MJ, Mi T, Maiti SN, Widhopf GF 2nd, Hurton LV, Thokala R, Singh H, Olivares S, Champlin RE, Wierda WG, Kipps TJ, Cooper LJ. Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations. PLoS One. 2015 Jun 1;10(6):e0128151. https://doi.org/10.1371/journal.pone.0128151
Kashyap MK, Kumar D, Villa R, La Clair JJ, Benner C, Sasik R, Jones H, Ghia EM, Rassenti LZ, Kipps TJ, Burkart MD, Castro JE. Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B. Haematologica. 2015 Jul;100(7):945-54. Epub 2015 Apr 10. https://doi.org/10.3324/haematol.2014.122069
Pereira DS, Guevara CI, Jin L, Mbong N, Verlinsky A, Hsu SJ, Aviña H, Karki S, Abad JD, Yang P, Moon SJ, Malik F, Choi MY, An Z, Morrison K, Challita-Eid PM, Doñate F, Joseph IB, Kipps TJ, Dick JE, Stover DR. AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML. Mol Cancer Ther. 2015 Jul;14(7):1650-60. Epub 2015 May 1. https://doi.org/10.1158/1535-7163.MCT-15-0067
Österborg A, Jewell RC, Padmanabhan-Iyer S, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Furman RR, Robak T, Hillmen P, Trnêný M, Dyer MJ, Piotrowska M, Kozak T, Gupta IV, Phillips JL, Goldstein N, Struemper H, Losic N, Lisby S, Wierda WG; Hx-CD20-406 Study Investigators. Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study. Haematologica. 2015 Aug;100(8):e311-4. Epub 2015 Mar 13. https://doi.org/10.3324/haematol.2014.121459
Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC Jr, Bennett JM, Benz EJ Jr, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ Jr, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O’Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA. In support of a patient-driven initiative and petition to lower the high price of cancer drugs. Mayo Clin Proc. 2015 Aug;90(8):996-1000. Epub 2015 Jul 23. https://doi.org/10.1016/j.mayocp.2015.06.001
Tili E, Chiabai M, Palmieri D, Brown M, Cui R, Fernandes C, Richmond T, Kim T, Sheetz T, Sun HL, Lagana A, Veneziano D, Volinia S, Rassenti L, Kipps T, Awad H, Michaille JJ, Croce CM. Quaking and miR-155 interactions in inflammation and leukemogenesis. Oncotarget. 2015 Sep 22;6(28):24599-610. https://doi.org/10.18632/oncotarget.5248
Patton WN, Lindeman R, Butler AC, Kipps TJ, Jewell RC, Laubscher KH, Zhou YY, Lewis E, Sedoti D, Witman P, Fang L, Chan G. An open-label, single-arm, phase 1 study to assess biomarker effects, efficacy and safety of ofatumumab in patients with refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2015 Oct;56(10):2819-25. Epub 2015 Sep 2. https://doi.org/10.3109/10428194.2015.1014357
Kipps TJ, Eradat H, Grosicki S, Catalano J, Cosolo W, Dyagil IS, Yalamanchili S, Chai A, Sahasranaman S, Punnoose E, Hurst D, Pylypenko H. A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2015 Oct;56(10):2826-33. Epub 2015 May 12. https://doi.org/10.3109/10428194.2015.1030638
Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O’Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ; RESONATE-2 Investigators. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015 Dec 17;373(25):2425-37. Epub 2015 Dec 6. https://doi.org/10.1056/NEJMoa1509388
O’Brien SM, Lamanna N, Kipps TJ, Flinn I, Zelenetz AD, Burger JA, Keating M, Mitra S, Holes L, Yu AS, Johnson DM, Miller LL, Kim Y, Dansey RD, Dubowy RL, Coutre SE. A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. Blood. 2015 Dec 17;126(25):2686-94. Epub 2015 Oct 15. https://doi.org/10.1182/blood-2015-03-630947

2016

Kipps TJ, Ghia EM, Rassenti LZ. Immunoglobulin Genes. In Detrick B, Schmitz JL, Hamilton RG, Eds. Manual of Molecular and Clinical Laboratory Immunology. Eighth Edition. ASM Press: Washington, DC; 2016: 51-64. https://doi.org/10.1128/9781555818722.ch6
Wendtner CM, Hallek M, Fraser GA, Michallet AS, Hillmen P, Dürig J, Kalaycio M, Gribben JG, Stilgenbauer S, Buhler A, Kipps TJ, Purse B, Zhang J, De Bedout S, Mei J, Chanan-Khan A. Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial. Leuk Lymphoma. 2016;57(6):1291-9. Epub 2016 Jan 14. https://doi.org/10.3109/10428194.2015.1128540
Byrd JC, Flynn JM, Kipps TJ, Boxer M, Kolibaba KS, Carlile DJ, Fingerle-Rowson G, Tyson N, Hirata J, Sharman JP. Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. Blood. 2016 Jan 7;127(1):79-86. Epub 2015 Oct 15. https://doi.org/10.1182/blood-2015-03-634394
Kashyap MK, Kumar D, Jones H, Amaya-Chanaga CI, Choi MY, Melo-Cardenas J, Ale-Ali A, Kuhne MR, Sabbatini P, Cohen LJ, Shelat SG, Rassenti LZ, Kipps TJ, Cardarelli PM, Castro JE. Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway. Oncotarget. 2016 Jan 19;7(3):2809-22. https://doi.org/10.18632/oncotarget.6465
Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, Kipps TJ, Anderson MA, Brown JR, Gressick L, Wong S, Dunbar M, Zhu M, Desai MB, Cerri E, Heitner Enschede S, Humerickhouse RA, Wierda WG, Seymour JF. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2016 Jan 28;374(4):311-22. Epub 2015 Dec 6. https://doi.org/10.1056/NEJMoa1513257
Yu J, Chen L, Cui B, Widhopf GF 2nd, Shen Z, Wu R, Zhang L, Zhang S, Briggs SP, Kipps TJ. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation. J Clin Invest. 2016 Feb;126(2):585-98. https://doi.org/10.1172/JCI83535
Castro JE, Kipps TJ. Adoptive cellular therapy for chronic lymphocytic leukemia and B cell malignancies. CARs and more. Best Pract Res Clin Haematol. 2016 Mar;29(1):15-29. Epub 2016 Aug 20. https://doi.org/10.1016/j.beha.2016.08.011
Oakes CC, Seifert M, Assenov Y, Gu L, Przekopowitz M, Ruppert AS, Wang Q, Imbusch CD, Serva A, Koser SD, Brocks D, Lipka DB, Bogatyrova O, Weichenhan D, Brors B, Rassenti L, Kipps TJ, Mertens D, Zapatka M, Lichter P, Döhner H, Küppers R, Zenz T, Stilgenbauer S, Byrd JC, Plass C. DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. Nat Genet. 2016 Mar;48(3):253-64. Epub 2016 Jan 18. https://doi.org/10.1038/ng.3488
Bühler A, Wendtner CM, Kipps TJ, Rassenti L, Fraser GA, Michallet AS, Hillmen P, Dürig J, Gregory SA, Kalaycio M, Aurran-Schleinitz T, Trentin L, Gribben JG, Chanan-Khan A, Purse B, Zhang J, De Bedout S, Mei J, Hallek M, Stilgenbauer S. Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. Blood Cancer J. 2016 Mar 11;6:e404. https://doi.org/10.1038/bcj.2016.9
Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J, Palacio C, Stehlikova O, Kreuzer KA, Liptrot S, O’Brien D, de Tute RM, Marinov I, Hauwel M, Spacek M, Dobber J, Kater AP, Gambell P, Soosapilla A, Lozanski G, Brachtl G, Lin K, Boysen J, Hanson C, Jorgensen JL, Stetler-Stevenson M, Yuan C, Broome HE, Rassenti L, Craig F, Delgado J, Moreno C, Bosch F, Egle A, Doubek M, Pospisilova S, Mulligan S, Westerman D, Sanders CM, Emerson R, Robins HS, Kirsch I, Shanafelt T, Pettitt A, Kipps TJ, Wierda WG, Cymbalista F, Hallek M, Hillmen P, Montserrat E, Ghia P. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia. 2016 Apr;30(4):929-36. Epub 2015 Dec 7. https://doi.org/10.1038/leu.2015.313
Van Dyke DL, Werner L, Rassenti LZ, Neuberg D, Ghia E, Heerema NA, Dal Cin P, Dell Aquila M, Sreekantaiah C, Greaves AW, Kipps TJ, Kay NE. The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience. Version 2. Br J Haematol. 2016 Apr;173(1):105-13. Epub 2016 Feb 5. https://doi.org/10.1111/bjh.13933
Burger JA, Styles L, Kipps TJ. Ibrutinib for Chronic Lymphocytic Leukemia. N Engl J Med. 2016 Apr 21;374(16):1594-5. https://doi.org/10.1056/NEJMc1600328
Manouchehri S, Ibsen S, Wright J, Rassenti L, Ghia EM, Widhopf GF 2nd, Kipps TJ, Heller MJ. Dielectrophoretic recovery of DNA from plasma for the identification of chronic lymphocytic leukemia point mutations. Int J Hematol Oncol. 2016 May;5(1):27-35. Epub 2016 May 5. https://doi.org/10.2217/ijh-2015-0009
Pekarsky Y, Balatti V, Palamarchuk A, Rizzotto L, Veneziano D, Nigita G, Rassenti LZ, Pass HI, Kipps TJ, Liu CG, Croce CM. Dysregulation of a family of short noncoding RNAs, tsRNAs, in human cancer. Proc Natl Acad Sci U S A. 2016 May 3;113(18):5071-6. Epub 2016 Apr 11. https://doi.org/10.1073/pnas.1604266113
Baggio C, Barile E, Di Sorbo G, Kipps TJ, Pellecchia M. The Cell Surface Receptor CD44: NMR-Based Characterization of Putative Ligands. ChemMedChem. 2016 May 19;11(10):1097-106. Epub 2016 May 4. https://doi.org/10.1002/cmdc.201600039
Brown JR, Harb WA, Hill BT, Gabrilove J, Sharman JP, Schreeder MT, Barr PM, Foran JM, Miller TP, Burger JA, Kelly KR, Mahadevan D, Ma S, Li Y, Pierce DW, Barnett E, Marine J, Miranda M, Azaryan A, Yu X, Nava-Parada P, Mei J, Kipps TJ. Phase I study of single-agent CC-292, a highly selective Bruton’s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia. Haematologica. 2016 Jul;101(7):e295-8. Epub 2016 May 5. https://doi.org/10.3324/haematol.2015.140806
Lampson BL, Kasar SN, Matos TR, Morgan EA, Rassenti L, Davids MS, Fisher DC, Freedman AS, Jacobson CA, Armand P, Abramson JS, Arnason JE, Kipps TJ, Fein J, Fernandes S, Hanna J, Ritz J, Kim HT, Brown JR. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016 Jul 14;128(2):195-203. Epub 2016 May 31. https://doi .org/10.1182/blood-2016-03-707133
Choi M, Kipps T, Kurzrock R. ATM mutations in cancer: therapeutic implications. Mol Cancer Ther. 2016 Aug;15(8):1781-91. Epub 2016 Jul 13. https://doi.org/10.1158/1535-7163.MCT-15-0945
Sattari A, Siddiqui H, Moshiri F, Ngankeu A, Nakamura T, Kipps TJ, Croce CM. Upregulation of long noncoding RNA MIAT in aggressive form of chronic lymphocytic leukemias. Oncotarget. 2016 Aug 23;7(34):54174-54182. https://doi.org/10.18632/oncotarget.11099
Choi MY, Kipps TJ. How do targeted therapies change the management of indolent lymphomas? Oncology (Williston Park). 2016 Sep 15;30(9):859-60. https://www.cancernetwork.com/view/how-do-targeted-therapies-change-management-indolent-lymphomas
Pavlasova G, Borsky M, Seda V, Cerna K, Osickova J, Doubek M, Mayer J, Calogero R, Trbusek M, Pospisilova S, Davids MS, Kipps TJ, Brown JR, Mraz M. Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis. Blood. 2016 Sep 22;128(12):1609-13. Epub 2016 Aug 1. https://doi.org/10.1182/blood-2016-04-709519
Kumar D, Kashyap MK, La Clair JJ, Villa R, Spaanderman I, Chien S, Rassenti LZ, Kipps TJ, Burkart MD, Castro JE. Selectivity in small molecule splicing modulation. ACS Chem Biol. 2016 Oct 21;11(10):2716-2723. Epub 2016 Aug 8. https://doi.org/10.1021/acschembio.6b00399
Wang L, Brooks AN, Fan J, Wan Y, Gambe R, Li S, Hergert S, Yin S, Freeman SS, Levin JZ, Fan L, Seiler M, Buonamici S, Smith PG, Chau KF, Cibulskis CL, Zhang W, Rassenti LZ, Ghia EM, Kipps TJ, Fernandes S, Bloch DB, Kotliar D, Landau DA, Shukla SA, Aster JC, Reed R, DeLuca DS, Brown JR, Neuberg D, Getz G, Livak KJ, Meyerson MM, Kharchenko PV, Wu CJ. Transcriptomic characterization of SF3B1 mutation reveals its pleiotropic effects in chronic lymphocytic leukemia. Cancer Cell. 2016 Nov 14;30(5):750-763. Epub 2016 Nov 3. https://doi.org/10.1016/j.ccell.2016.10.005
Mato A, Nabhan C, Kay NE, Weiss MA, Lamanna N, Kipps TJ, Grinblatt DL, Flinn IW, Kozloff MF, Flowers CR, Farber CM, Kiselev P, Swern AS, Sullivan K, Flick ED, Sharman JP. Real-world clinical experience in the Connect® chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres. Br J Haematol. 2016 Dec;175(5):892-903. Epub 2016 Nov 8. https://doi.org/10.1111/bjh.14332
Cui B, Ghia EM, Chen L, Rassenti LZ, DeBoever C, Widhopf GF 2nd, Yu J, Neuberg DS, Wierda WG, Rai KR, Kay NE, Brown JR, Jones JA, Gribben JG, Frazer KA, Kipps TJ. High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. Blood. 2016 Dec 22;128(25):2931-2940. Epub 2016 Nov 4. https://doi.org/10.1182/blood-2016-04-712562

2017

Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG, O’Brien S, Gribben J, Rai K. Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017 Jan 19;3:16096. https://doi.org/10.1038/nrdp.2016.96
Jewell RC, Kipps TJ, Dürig J, Griskevicius L, Stilgenbauer S, Smolej L, Mayer J, Hess G, Hernandez-Ilizaliturri FJ, Padmanabhan-Iyer S, Fang L, Goldstein N, Gorczyca M, Gupta I, Lisby S, Wierda WG; Hx-CD20-407 Study Investigators. Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy. Leuk Lymphoma. 2017 Feb;58(2):348-356. Epub 2016 Jul 7. https://doi.org/10.1080/10428194.2016.1195497
Seymour JF, Ma S, Brander DM, Choi MY, Barrientos J, Davids MS, Anderson MA, Beaven AW, Rosen ST, Tam CS, Prine B, Agarwal SK, Munasinghe W, Zhu M, Lash LL, Desai M, Cerri E, Verdugo M, Kim SY, Humerickhouse RA, Gordon GB, Kipps TJ, Roberts AW. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol. 2017 Feb;18(2):230-240. Epub 2017 Jan 13. https://doi.org/10.1016/S1470-2045(17)30012-8
Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG, O’Brien S, Gribben J, Rai K. Correction. Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017 Feb 9;3:17008. https://doi.org/10.1038/nrdp.2017.8
Barile E, Marconi GD, De SK, Baggio C, Gambini L, Salem AF, Kashyap MK, Castro JE, Kipps TJ, Pellecchia M. hBfl-1/hNOXA interaction studies provide new insights on the role of Bfl-1 in cancer cell resistance and for the design of novel anticancer agents. ACS Chem Biol. 2017 Feb 17;12(2):444-455. Epub 2016 Dec 27. https://doi.org/10.1021/acschembio.6b00962
Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, Puvvada S, Kipps TJ, Anderson MA, Salem AH, Dunbar M, Zhu M, Peale F, Ross JA, Gressick L, Desai M, Kim SY, Verdugo M, Humerickhouse RA, Gordon GB, Gerecitano JF. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017 Mar 10;35(8):826-833. Epub 2017 Jan 17. https://doi.org/10.1200/JCO.2016.70.4320
Zhou Y, Kipps TJ, Zhang S. Wnt5a Signaling in Normal and Cancer Stem Cells. Stem Cells Int. 2017;2017:5295286. Epub 2017 Apr 12. https://doi.org/10.1155/2017/5295286
Miller CR, Ruppert AS, Fobare S, Chen TL, Liu C, Lehman A, Blachly JS, Zhang X, Lucas DM, Grever MR, Tallman MS, Flinn IW, Rassenti LZ, Kipps TJ, Sampath D, Coombes KR, Hertlein EK. The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia. Oncotarget. 2017 Apr 18;8(16):25942-25954. https://doi.org/10.18632/oncotarget.15401
Fischer K, Al-Sawaf O, Fink AM, Dixon M, Bahlo J, Warburton S, Kipps TJ, Weinkove R, Robinson S, Seiler T, Opat S, Owen C, López J, Humphrey K, Humerickhouse R, Tausch E, Frenzel L, Eichhorst B, Wendtner CM, Stilgenbauer S, Langerak AW, van Dongen JJM, Böttcher S, Ritgen M, Goede V, Mobasher M, Hallek M. Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood. 2017 May 11;129(19):2702-2705. Epub 2017 Mar 21. https://doi.org/10.1182/blood-2017-01-761973
Kashyap MK, Amaya-Chanaga CI, Kumar D, Simmons B, Huser N, Gu Y, Hallin M, Lindquist K, Yafawi R, Choi MY, Amine AA, Rassenti LZ, Zhang C, Liu SH, Smeal T, Fantin VR, Kipps TJ, Pernasetti F, Castro JE. Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia. J Hematol Oncol. 2017 May 19;10(1):112. https://doi.org/10.1186/s13045-017-0435-x
Yu J, Chen L, Cui B, Wu C, Choi MY, Chen Y, Zhang L, Rassenti LZ, Widhopf II GF, Kipps TJ. Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib. Version 2. Leukemia. 2017 Jun;31(6):1333-1339. Epub 2016 Dec 1. https://doi.org/10.1038/leu.2016.368
Murphy EJ, Neuberg DS, Rassenti LZ, Hayes Greg, Redd R, Emson C, Li K, McConnel C, Greaves A, Turner S, Brown J, Weirda W, Byrd J, Zent C, Kay N, Barrientos J, Hellerstein M, Chiorazzi N, Kipps TJ, Rai KR. Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia. Leukemia. 2017 Jun;31(6):1348-1354. Epub 2017 Jan 24. https://doi.org/10.1038/leu.2017.34
Jones JA, Hillmen P, Coutre S, Tam C, Furman RR, Barr PM, Schuster SJ, Kipps TJ, Flinn IW, Jaeger U, Burger JA, Cheng M, Ninomoto J, James DF, Byrd JC, O’Brien SM. Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. Br J Haematol. 2017 Jul;178(2):286-291. Epub 2017 Apr 10. https://doi.org/10.1111/bjh.14660
Young E, Noerenberg D, Mansouri L, Ljungström V, Frick M, Sutton L-A, Blakemore S, Galan-Sousa J, Plevova K, Baliakas P, Rossi D, Clifford R, Roos-Weil D, Navrkalova V, Dörken B, Schmitt C, Ekstrom Smedby K, Juliusson G, Giacopelli B, Blachly J, Belessi C, Chiorazzi N, Panayiotidis P, Davi F, Langerak A, Oscier D, Schuh A, Gaidano G, Ghia P, Xu W, Fan L, Bernard O, N’Guyen Khac F, Rassenti L, Li J, Kipps TJ, Stamatopoulos K, Pospisilova S, Zenz T, Oakes C, Strefford J, Rosenquist R, Damm F. EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia. Leukemia. 2017 Jul;31(7):1547-1554. Epub 2016 Nov 28. https://doi.org/10.1038/leu.2016.359
Zhou Y, Kipps TJ, Zhang S. Corrigendum to “Wnt5a Signaling in Normal and Cancer Stem Cells”. Stem Cells Int. 2017;2017:3467360. Epub 2017 Sep 27. https://doi.org/10.1155/2017/3467360
Brown JR, Moslehi J, O’Brien S, Ghia P, Hillmen P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Kipps TJ, Coutre S, Dilhuydy MS, Cramer P, Tedeschi A, Jaeger U, Dreyling M, Byrd JC, Howes A, Todd M, Vermeulen J, James DF, Clow F, Styles L, Valentino R, Wildgust M, Mahler M, Burger JA. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017 Oct;102(10):1796-1805. Epub 2017 Jul 27. https://doi.org/10.3324/haematol.2017.171041
Rassenti LZ, Balatti V, Ghia EM, Palamarchuk A, Tomasello L, Fadda P, Pekarsky Y, Widhopf GF 2nd, Kipps TJ, Croce CM. MicroRNA dysregulation to identify therapeutic target combinations for chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10731-10736. Epub 2017 Sep 18. https://doi.org/10.1073/pnas.1708264114
Wierda WG, Byrd JC, Abramson JS, Bhat S, Bociek G, Brander D, Brown J, Chanan-Khan A, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lancet J, Ma S, Malek S, Mosse C, Shadman M, Siddiqi T, Stephens D, Wagner N, Zelenetz AD, Dwyer MA, Sundar H. Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Nov;15(11):1414-1427. https://doi.org/10.6004/jnccn.2017.0165
Yu J, Chen L, Chen Y, Hasan MK, Ghia EM, Zhang L, Wu R, Rassenti LZ, Widhopf GF, Shen Z, Briggs SP, Kipps TJ. Wnt5a induces ROR1 to associate with 14-3-3ζ for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells. Version 2. Leukemia. 2017 Dec;31(12):2608-2614. Epub 2017 May 3. https://doi.org/10.1038/leu.2017.132
Hasan MK, Yu J, Chen L, Cui B, Widhopf Ii GF, Rassenti L, Shen Z, Briggs SP, Kipps TJ. Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells. Version 2. Leukemia. 2017 Dec;31(12):2615-2622. Epub 2017 May 3. https://doi.org/10.1038/leu.2017.133

2018

Brown JR, Hillmen P, O’Brien S, Barrientos JC, Reddy NM, Coutre SE, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Thornton P, Caligaris-Cappio F, Delgado J, Montillo M, DeVos S, Moreno C, Pagel JM, Munir T, Burger JA, Chung D, Lin J, Gau L, Chang B, Cole G, Hsu E, James DF, Byrd JC. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. Leukemia. 2018 Jan;32(1):83-91. Epub 2017 Jun 8. https://doi.org/10.1038/leu.2017.175
Mato A, Nabhan C, Kay NE, Lamanna N, Kipps TJ, Grinblatt DL, Flowers CR, Farber CM, Davids MS, Kiselev P, Swern AS, Bhushan S, Sullivan K, Flick ED, Sharman JP. Prognostic testing patterns and outcomes of chronic lymphocytic leukemia patients stratified by fluorescence in situ hybridization/cytogenetics: a real-world clinical experience in the connect CLL registry. Clin Lymphoma Myeloma Leuk. 2018 Feb;18(2):114-124.e2. Epub 2017 Dec 6. https://doi.org/10.1016/j.clml.2017.11.010
Sivina M, Werner L, Rassenti L, Ferrajoli A, Wierda WG, Keating MJ, O’Brien S, Neuberg D, Kipps T, Burger JA. Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation. Br J Haematol. 2018 Feb;180(4):597-600. Epub 2016 Oct 21. https://doi.org/10.1111/bjh.14398
Gonzalez VD, Samusik N, Chen TJ, Savig ES, Aghaeepour N, Quigley DA, Huang YW, Giangarrà V, Borowsky AD, Hubbard NE, Chen SY, Han G, Ashworth A, Kipps TJ, Berek JS, Nolan GP, Fantl WJ. Commonly occurring cell subsets in high-grade serous ovarian tumors identified by single-cell mass cytometry. Cell Rep. 2018 Feb 13;22(7):1875-1888. https://doi.org/10.1016/j.celrep.2018.01.053
Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D’Rozario J, Assouline S, Owen C, Gerecitano J, Robak T, De la Serna J, Jaeger U, Cartron G, Montillo M, Humerickhouse R, Punnoose EA, Li Y, Boyer M, Humphrey K, Mobasher M, Kater AP. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018 Mar 22;378(12):1107-1120. https://doi.org/10.1056/NEJMoa1713976
O’Brien SM, Jaglowski S, Byrd JC, Bannerji R, Blum KA, Fox CP, Furman RR, Hillmen P, Kipps TJ, Montillo M, Sharman J, Suzuki S, James DF, Chu AD, Coutre SE. Prognostic factors for complete response to ibrutinib in patients with chronic lymphocytic leukemia: a pooled analysis of 2 clinical trials. JAMA Oncol. 2018 May 1;4(5):712-716. https://doi.org/10.1001/jamaoncol.2017.5604
Yu J, Chen Y, Chen L, Zhang L, Rassenti LZ, Widhopf GF 2nd, Kipps TJ. Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma. Oncotarget. 2018 May 15;9(37):24731-24736. https://doi.org/10.18632/oncotarget.25340
Coutre S, Tedeschi A, Robak T, Barr PM, Owen C, Bairey O, Burger J, Zhou C, Styles L, James DF, Kipps TJ. Survival adjusting for crossover: phase 3 study of ibrutinib vs. chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma. Haematologica. 2018 Jun;103(6):e249-e251. Epub 2017 Nov 23. https://doi.o rg/10.3324/haematol.2017.175380
Choi MY, Widhopf GF 2nd, Ghia EM, Kidwell RL, Hasan MK, Yu J, Rassenti LZ, Chen L, Chen Y, Pittman E, Pu M, Messer K, Prussak CE, Castro JE, Jamieson C, Kipps TJ. Phase I trial: cirmtuzumab inhibits ROR1 signaling and stemness signatures in patients with chronic lymphocytic leukemia. Cell Stem Cell. 2018 Jun 1;22(6):951-959.e3. https://doi.org/10.1016/j.stem.2018.05.018
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O’Brien S, Robak T, Seymour JF, Kipps TJ. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018 Jun 21;131(25):2745-2760. Epub 2018 Mar 14. https://doi.org/10.1182/blood-2017-09-806398
Hasan MK, Yu J, Widhopf GF 2nd, Rassenti LZ, Chen L, Shen Z, Briggs SP, Neuberg DS, Kipps TJ. Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia. Blood. 2018 Jul 12;132(2):170-178. Epub 2018 Apr 20. https://doi.org/10.1182/blood-2017-12-819383
Barr PM, Robak T, Owen C, Tedeschi A, Bairey O, Bartlett NL, Burger JA, Hillmen P, Coutre S, Devereux S, Grosicki S, McCarthy H, Li J, Simpson D, Offner F, Moreno C, Zhou C, Styles L, James D, Kipps TJ, Ghia P. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica. 2018 Sep;103(9):1502-1510. Epub 2018 Jun 7. https://doi.org/10.3324/haematol.2018.192328
Ten Hacken E, Valentin R, Regis FFD, Sun J, Yin S, Werner L, Deng J, Gruber M, Wong J, Zheng M, Gill AL, Seiler M, Smith P, Thomas M, Buonamici S, Ghia EM, Kim E, Rassenti LZ, Burger JA, Kipps TJ, Meyerson ML, Bachireddy P, Wang L, Reed R, Neuberg D, Carrasco RD, Brooks AN, Letai A, Davids MS, Wu CJ. Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI Insight. 2018 Oct 4;3(19):e121438. https://doi.org/10.1172/jci.insight.121438
Robak T, Burger JA, Tedeschi A, Barr PM, Owen C, Bairey O, Hillmen P, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre SE, Quach H, Gaidano G, Maslyak Z, Stevens DA, Moreno C, Gill DS, Flinn IW, Gribben JG, Mokatrin A, Cheng M, Styles L, James DF, Kipps TJ, Ghia P. Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies. Am J Hematol. 2018 Nov;93(11):1402-1410. Epub 2018 Oct 9. https://doi.org/10.1002/ajh.25259
Balatti V, Tomasello L, Rassenti LZ, Veneziano D, Nigita G, Wang HY, Thorson JA, Kipps TJ, Pekarsky Y, Croce CM. miR-125a and miR-34a expression predicts Richter syndrome in chronic lymphocytic leukemia patients. Blood. 2018 Nov 15;132(20):2179-2182. Epub 2018 Sep 21. https://doi.org/10.1182/blood-2018-04-845115

2019

Castro JE, Kipps TJ. Chimeric antigen receptor T cells: antigen selection, CAR development, and data in neoplastic hematology. In Perales MA, Abutalib SA, Bollard C, Eds. Cell and Gene Therapies. Boston, MA: Springer; 2019: 27-53. https://doi.org/10.1007/978-3-319-54368-0_3
Castro JE, Kipps TJ. Gene therapy for neoplastic hematology in transplant setting. In Perales MA, Abutalib SA, Bollard C, Eds. Cell and Gene Therapies. Boston, MA: Springer; 2019: 245-264. https://doi.org/10.1007/978-3-319-54368-0_13
Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Ma S, Malek S, Mato A, Mosse C, Neppalli VT, Shadman M, Siddiqi T, Stephens D, Wagner N, Dwyer MA, Sundar H. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019. J Natl Compr Canc Netw. 2019 Jan;17(1):12-20. https://doi.org/10.6004/jnccn.2019.0002
Zhang S, Zhang H, Ghia EM, Huang J, Wu L, Zhang J, Lam S, Lei Y, He J, Cui B, Widhopf GF 2nd, Yu J, Schwab R, Messer K, Jiang W, Parker BA, Carson DA, Kipps TJ. Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody. Proc Natl Acad Sci U S A. 2019 Jan 22;116(4):1370-1377. Epub 2019 Jan 8. https://doi.org/10.1073/pnas.1816262116
Brander DM, Friedman DR, Volkheimer AD, Christensen DJ, Rassenti LZ, Kipps TJ, Guadalupe E, Chen Y, Zhang D, Wang X, Davis C, Owzar K, Weinberg JB. SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia. Br J Haematol. 2019 Feb;184(4):605-615. Epub 2018 Nov 15. https://doi.org/10.1111/bjh.15677
Kater AP, Seymour JF, Hillmen P, Eichhorst B, Langerak AW, Owen C, Verdugo M, Wu J, Punnoose EA, Jiang Y, Wang J, Boyer M, Humphrey K, Mobasher M, Kipps TJ. Fixed duration of venetoclax-rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study. J Clin Oncol. 2019 Feb 1;37(4):269-277. Epub 2018 Dec 3. https://doi.org/10.1200/JCO.18.01580
Yin S, Gambe RG, Sun J, Martinez AZ, Cartun ZJ, Regis FFD, Wan Y, Fan J, Brooks AN, Herman SEM, Ten Hacken E, Taylor-Weiner A, Rassenti LZ, Ghia EM, Kipps TJ, Obeng EA, Cibulskis CL, Neuberg D, Campagna DR, Fleming MD, Ebert BL, Wiestner A, Leshchiner I, DeCaprio JA, Getz G, Reed R, Carrasco RD, Wu CJ, Wang L. A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion. Cancer Cell. 2019 Feb 11;35(2):283-296.e5. Epub 2019 Jan 31. https://doi.org/10.1016/j.ccell.2018.12.013
Brown JR, O’Brien S, Kingsley CD, Eradat H, Pagel JM, Hirata J, McIver T, Morariu-Zamfir R, Kipps TJ. Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL. Blood. 2019 Feb 28;133(9):990-992. Epub 2018 Dec 28. https://doi.org/10.1182/blood-2018-06-857714
Hasan MK, Rassenti L, Widhopf GF 2nd, Yu J, Kipps TJ. Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells. Leukemia. 2019 Mar;33(3):653-661. Epub 2018 Dec 19. https://doi.org/10.1038/s41375-018-0306-7
Barrientos JC, Burger JA, Byrd JC, Hillmen P, Zhou C, Ninomoto J, James DF, Kipps TJ. Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib. Leuk Lymphoma. 2019 Apr;60(4):1000-1005. Epub 2018 Oct 2. https://doi.org/10.1080/10428194.2018.1512710
Lampson BL, Kim HT, Davids MS, Abramson JS, Freedman AS, Jacobson CA, Armand PA, Joyce RM, Arnason JE, Rassenti LZ, Kipps TJ, Fein J, Fernandes SM, Hanna JR, Fisher DC, Brown JR. Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia. Blood Adv. 2019 Apr 9;3(7):1167-1174. https://doi.org/10.1182/bloodadvances.2018030221
Pagotto S, Veronese A, Soranno A, Balatti V, Ramassone A, Guanciali-Franchi PE, Palka G, Innocenti I, Autore F, Rassenti LZ, Kipps TJ, Mariani-Costantini R, Laurenti L, Croce CM, Visone R. HNRNPL Restrains miR-155 Targeting of BUB1 to Stabilize Aberrant Karyotypes of Transformed Cells in Chronic Lymphocytic Leukemia. Cancers (Basel). 2019 Apr 23;11(4):575. https://doi.org/10.3390/cancers11040575
O’Brien SM, Byrd JC, Hillmen P, Coutre S, Brown JR, Barr PM, Barrientos JC, Devereux S, Robak T, Reddy NM, Kipps TJ, Tedeschi A, Cymbalista F, Ghia P, Chang S, Ninomoto J, James DF, Burger JA. Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. Am J Hematol. 2019 May;94(5):554-562. Epub 2019 Mar 8. https://doi.org/10.1002/ajh.25436
Byrd JC, Hillmen P, O’Brien S, Barrientos JC, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Thornton P, Moreno C, Montillo M, Pagel JM, Burger JA, Woyach JA, Dai S, Vezan R, James DF, Brown JR. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood. 2019 May 9;133(19):2031-2042. Epub 2019 Mar 6. https://doi.org/10.1182/blood-2018-08-870238
Choi MY, Wang HY, Kipps TJ. SOHO state of the art updates and next questions: the conundrum in assessing the therapy response of patients with chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):321-325. Epub 2019 May 29. https://doi.org/10.1016/j.clml.2019.05.013
Gruber M, Bozic I, Leshchiner I, Livitz D, Stevenson K, Rassenti L, Rosebrock D, Taylor-Weiner A, Olive O, Goyetche R, Fernandes SM, Sun J, Stewart C, Wong A, Cibulskis C, Zhang W, Reiter JG, Gerold JM, Gribben JG, Rai KR, Keating MJ, Brown JR, Neuberg D, Kipps TJ, Nowak MA, Getz G, Wu CJ. Growth dynamics in naturally progressing chronic lymphocytic leukaemia. Nature. 2019 Jun;570(7762):474-479. Epub 2019 May 29. https://doi.org/10.1038/s41586-019-1252-x
Sharman JP, Coutre SE, Furman RR, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn IW, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Tausch E, Cramer P, Huang J, Mitra S, Hallek M, O’Brien SM, Stilgenbauer S. Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia. J Clin Oncol. 2019 Jun 1;37(16):1391-1402. Epub 2019 Apr 17. https://doi.org/10.1200/JCO.18.01460
Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, Robrecht S, Warburton S, Humphrey K, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Dû K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ, Boettcher S, Tausch E, Humerickhouse R, Eichhorst B, Wendtner CM, Langerak AW, Kreuzer KA, Ritgen M, Goede V, Stilgenbauer S, Mobasher M, Hallek M. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019 Jun 6;380(23):2225-2236. Epub 2019 Jun 4. https://doi.org/10.1056/NEJMoa1815281
Ghia EM, Rassenti LZ, Neuberg DS, Blanco A, Yousif F, Smith EN, McPherson JD, Hudson TJ; HALT Pan-Leukemia Gene Panel Consortium, Harismendy O, Frazer KA, Kipps TJ. Activation of hedgehog signaling associates with early disease progression in chronic lymphocytic leukemia. Blood. 2019 Jun 20;133(25):2651-2663. Epub 2019 Mar 28. https://doi.org/10.1182/blood-2018-09-873695
Coutre SE, Byrd JC, Hillmen P, Barrientos JC, Barr PM, Devereux S, Robak T, Kipps TJ, Schuh A, Moreno C, Furman RR, Burger JA, O’Dwyer M, Ghia P, Valentino R, Chang S, Dean JP, James DF, O’Brien SM. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv. 2019 Jun 25;3(12):1799-1807. https://doi.org/10.1182/bloodadvances.2018028761
Flinn IW, Gribben JG, Dyer MJS, Wierda W, Maris MB, Furman RR, Hillmen P, Rogers KA, Iyer SP, Quillet-Mary A, Ysebaert L, Walter HS, Verdugo M, Klein C, Huang H, Jiang Y, Lozanski G, Pignataro DS, Humphrey K, Mobasher M, Kipps TJ. Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. Blood. 2019 Jun 27;133(26):2765-2775. Epub 2019 Mar 12. https://doi.org/10.1182/blood-2019-01-896290
Wierda WG, Byrd JC, O’Brien S, Coutre S, Barr PM, Furman RR, Kipps TJ, Burger JA, Stevens DA, Sharman J, Ghia P, Flinn IW, Zhou C, Ninomoto J, James DF, Tam CS. Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia. Br J Haematol. 2019 Jul;186(1):184-188. Epub 2019 Feb 10. https://doi.org/10.1111/bjh.15791
Roberts AW, Ma S, Kipps TJ, Coutre SE, Davids MS, Eichhorst B, Hallek M, Byrd JC, Humphrey K, Zhou L, Chyla B, Nielsen J, Potluri J, Kim SY, Verdugo M, Stilgenbauer S, Wierda WG, Seymour JF. Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Blood. 2019 Jul 11;134(2):111-122. Epub 2019 Apr 25. https://doi.org/10.1182/blood.2018882555
Giacopelli B, Zhao Q, Ruppert AS, Agyeman A, Weigel C, Wu YZ, Gerber MM, Rabe KG, Larson MC, Lu J, Blachly JS, Rogers KA, Wierda WG, Brown JR, Rai KR, Keating M, Rassenti LZ, Kipps TJ, Zenz T, Shanafelt TD, Kay NE, Abruzzo LV, Coombes KR, Woyach JA, Byrd JC, Oakes CC. Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia. Blood. 2019 Aug 22;134(8):688-698. Epub 2019 Jul 10. https://doi.org/10.1182/blood.2019000490
Chen Y, Chen L, Yu J, Ghia EM, Choi MY, Zhang L, Zhang S, Sanchez-Lopez E, Widhopf GF 2nd, Messer K, Rassenti LZ, Jamieson C, Kipps TJ. Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-κB to repress autocrine STAT3 activation in chronic lymphocytic leukemia. Blood. 2019 Sep 26;134(13):1084-1094. Epub 2019 Aug 13. https://doi.org/10.1182/blood.2019001366
Udd KA, Bujarski S, Wirtschafter E, Spektor TM, Ghermezi M, Rassenti LZ, David ME, Nosrati JD, Rahbari AA, Wang J, Vardanyan S, Harutyunyan NM, Linesch J, Li M, Sanchez E, Chen H, Kipps TJ, Berenson JR. Plasma B-Cell Maturation Antigen Levels are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia. Target Oncol. 2019 Oct;14(5):551-561. https://doi.org/10.1007/s11523-019-00666-0
Hasan MK, Widhopf GF 2nd, Zhang S, Lam SM, Shen Z, Briggs SP, Parker BA, Kipps TJ. Wnt5a induces ROR1 to recruit cortactin to promote breast-cancer migration and metastasis. NPJ Breast Cancer. 2019 Oct 25;5:35. https://doi.org/10.1038/s41523-019-0131-9
Kipps TJ, Fraser G, Coutre SE, Brown JR, Barrientos JC, Barr PM, Byrd JC, O’Brien SM, Dilhuydy MS, Hillmen P, Jaeger U, Moreno C, Cramer P, Stilgenbauer S, Chanan-Khan AA, Mahler M, Salman M, Eckert K, Solman IG, Balasubramanian S, Cheng M, Londhe A, Ninomoto J, Howes A, James DF, Hallek M. Long-term studies assessing outcomes of ibrutinib therapy in patients with del(11q) chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2019 Nov;19(11):715-722.e6. Epub 2019 Jul 15. https://doi.org/10.1016/j.clml.2019.07.004
Ramassone A, D’Argenio A, Veronese A, Basti A, Soliman SHA, Volinia S, Bassi C, Pagotto S, Ferracin M, Lupini L, Saccenti E, Balatti V, Pepe F, Rassenti LZ, Innocenti I, Autore F, Marzetti L, Mariani-Costantini R, Kipps TJ, Negrini M, Laurenti L, Visone R. Genetic dynamics in untreated CLL patients with either stable or progressive disease: a longitudinal study. J Hematol Oncol. 2019 Nov 19;12(1):114. https://doi.org/10.1186/s13045-019-0802-x
Veneziano D, Tomasello L, Balatti V, Palamarchuk A, Rassenti LZ, Kipps TJ, Pekarsky Y, Croce CM. Dysregulation of different classes of tRNA fragments in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2019 Nov 26;116(48):24252-24258. Epub 2019 Nov 13. https://doi.org/10.1073/pnas.1913695116
Kipps TJ, Choi MY. Targeted Therapy in Chronic Lymphocytic Leukemia. Cancer J. 2019 Nov/Dec;25(6):378-385. https://doi.org/10.1097/PPO.0000000000000416
Andritsos LA, Byrd JC, Cheverton P, Wu J, Sivina M, Kipps TJ, Burger JA. A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2019 Dec;60(14):3461-3469. Epub 2019 Jul 27. https://doi.org/10.1080/10428194.2019.1643463
Munir T, Brown JR, O’Brien S, Barrientos JC, Barr PM, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Kipps TJ, Moreno C, Montillo M, Burger JA, Byrd JC, Hillmen P, Dai S, Szoke A, Dean JP, Woyach JA. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019 Dec;94(12):1353-1363. Epub 2019 Oct 13. https://doi.org/10.1002/ajh.25638

2020

Lujan JV, Lengerke-Diaz PA, Jacobs C, Moreno-Cortes EF, Ramirez-Segura CA, Choi MY, McCarthy C, Heinen A, Kipps TJ, Castro JE. Ibrutinib reduces obinutuzumab infusion-related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels. Haematologica. 2020 Jan;105(1):e22-e25. Epub 2019 May 2. https://doi.org/10.3324/haematol.2018.212597
Sanchez-Lopez E, Ghia EM, Antonucci L, Sharma N, Rassenti LZ, Xu J, Sun B, Kipps TJ, Karin M. NF-κB-p62-NRF2 survival signaling is associated with high ROR1 expression in chronic lymphocytic leukemia. Cell Death Differ. 2020 Jan 28. [Epub ahead of print] https://doi.org/10.1038/s41418-020-0496-1
Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lim MS, Ma S, Malek S, Mato A, Mosse C, Shadman M, Siddiqi T, Stephens D, Sundaram S, Wagner N, Dwyer M, Sundar H. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 Feb;18(2):185-217. https://doi.org/10.6004/jnccn.2020.0006
Burger JA, Barr PM, Robak T, Owen C, Ghia P, Tedeschi A, Bairey O, Hillmen P, Coutre SE, Devereux S, Grosicki S, McCarthy H, Simpson D, Offner F, Moreno C, Dai S, Lal I, Dean JP, Kipps TJ. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020 Mar;34(3):787-798. Epub 2019 Oct 18. https://doi.org/10.1038/s41375-019-0602-x
Zhang J, Lin X, Wu L, Huang JJ, Jiang WQ, Kipps TJ, Zhang S. Aurora B induces epithelial-mesenchymal transition by stabilizing Snail1 to promote basal-like breast cancer metastasis. Oncogene. 2020 Mar;39(12):2550-2567. Epub 2020 Jan 29. https://doi.org/10.1038/s41388-020-1165-z
Tedeschi A, Greil R, Demirkan F, Robak T, Moreno C, Barr PM, Anz B, Simpson D, Gaidano G, Bairey O, Stevens D, Gill D, Flinn IW, Kipps TJ, Burger JA, Lin J, Webb T, Fedorov V, Styles L, Gribben JG. A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Haematologica. 2020 Apr;105(4):e164-e168. Epub 2019 Aug 14. https://doi.org/10.3324/haematol.2019.223743
Sanchez-Lopez E, Ghia EM, Antonucci L, Sharma N, Rassenti LZ, Xu J, Sun B, Kipps TJ, Karin M. NF-κB-p62-NRF2 survival signaling is associated with high ROR1 expression in chronic lymphocytic leukemia. Cell Death Differ. 2020 Jul;27(7):2206-2216. Epub 2020 Jan 28. https://doi.org/10.1038/s41418-020-0496-1
Al-Sawaf O, Zhang C, Tandon M, Sinha A, Fink AM, Robrecht S, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Dû K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ, Tausch E, Schary W, Ritgen M, Wendtner CM, Kreuzer KA, Eichhorst B, Stilgenbauer S, Hallek M, Fischer K. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020 Sep;21(9):1188-1200. https://doi.org/10.1016/S1470-2045(20)30443-5
Bachireddy P, Ennis C, Nguyen VN, Gohil SH, Clement K, Shukla SA, Forman J, Barkas N, Freeman S, Bavli N, Elagina L, Leshchiner I, Mohammad AW, Mathewson ND, Keskin DB, Rassenti LZ, Kipps TJ, Brown JR, Getz G, Ho VT, Gnirke A, Neuberg D, Soiffer RJ, Ritz J, Alyea EP, Kharchenko PV, Wu CJ. Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect. Sci Transl Med. 2020 Sep 16;12(561):eabb7661. https://doi.org/10.1126/scitranslmed.abb7661
Kater AP, Wu JQ, Kipps T, Eichhorst B, Hillmen P, D’Rozario J, Assouline S, Owen C, Robak T, de la Serna J, Jaeger U, Cartron G, Montillo M, Dubois J, Eldering E, Mellink C, Van Der Kevie-Kersemaekers AM, Kim SY, Chyla B, Punnoose E, Bolen CR, Assaf ZJ, Jiang Y, Wang J, Lefebure M, Boyer M, Humphrey K, Seymour JF. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study. J Clin Oncol. 2020 Sep 28:JCO2000948. Epub 2020 Dec 1. https://doi.org/10.1200/JCO.20.00948
Solman IG, Blum LK, Hoh HY, Kipps TJ, Burger JA, Barrientos JC, O’Brien S, Mulligan SP, Kay NE, Hillmen P, Byrd JC, Lal ID, Dean JP, Mongan A. Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia. Leuk Res. 2020 Oct;97:106432. Epub 2020 Aug 11. https://doi.org/10.1016/j.leukres.2020.106432
Hasan MK, Ghia EM, Rassenti LZ, Widhopf GF 2nd, Kipps TJ. Wnt5a enhances proliferation of chronic lymphocytic leukemia and ERK1/2 phosphorylation via a ROR1/DOCK2-dependent mechanism. Leukemia. 2020 Oct 23. [Epub ahead of print] https://doi.org/ 10.1038/s41375-020-01055-7
Sharma S, Pavlasova GM, Seda V, Cerna KA, Vojackova E, Filip D, Ondrisova L, Sandova V, Kostalova L, Zeni PF, Borsky M, Oppelt J, Liskova K, Kren L, Janikova A, Pospisilova S, Fernandes SM, Shehata M, Rassenti LZ, Jaeger U, Doubek M, Davids MS, Brown JR, Mayer J, Kipps TJ, Mraz M. miR-29 Modulates CD40 Signaling in Chronic Lymphocytic Leukemia by Targeting TRAF4: an Axis Affected by BCR inhibitors. Blood. 2020 Nov 10:blood.2020005627. [Epub ahead of print] https://doi.org/10.1182/blood.2020005627

2021

Kretzmer H, Biran A, Purroy N, Lemvigh C, Clement K, Gruber M, Gu H, Rassenti L, Mohammad AW, Lesnick C, Slager SL, Braggio E, Shanafelt TD, Kay NE, Fernandes S, Brown JR, Wang L, Li S, Livak KJ, Neuberg DS, Klages S, Timmermann B, Kipps TJ, Campo E, Gnirke A, Wu CJ, Meissner A. Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy. Blood Cancer Discov. 2021 Jan;2(1):54-69. https://doi.org/10.1158/2643-3230.BCD-19-0058 Epub 2020 Dec 3.
Walker JS, Hing ZA, Harrington B, Baumhardt J, Ozer HG, Lehman A, Giacopelli B, Beaver L, Williams K, Skinner JN, Cempre CB, Sun Q, Shacham S, Stromberg BR, Summers MK, Abruzzo LV, Rassenti L, Kipps TJ, Parikh S, Kay NE, Rogers KA, Woyach JA, Coppola V, Chook YM, Oakes C, Byrd JC, Lapalombella R. Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia. J Hematol Oncol. 2021 Jan 15;14(1):17. https://doi.org/10.1186/s13045-021-01032-2
Solman IG, Blum LK, Burger JA, Kipps TJ, Dean JP, James DF, Mongan A. Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia. Leuk Res. 2021 Mar;102:106520. Epub 2021 Feb 5. https://doi.org/ 10.1016/j.leukres.2021.106520
Lazarian G, Yin S, Ten Hacken E, Sewastianik T, Uduman M, Font-Tello A, Gohil SH, Li S, Kim E, Joyal H, Billington L, Witten E, Zheng M, Huang T, Severgnini M, Lefebvre V, Rassenti LZ, Gutierrez C, Georgopoulos K, Ott CJ, Wang L, Kipps TJ, Burger JA, Livak KJ, Neuberg DS, Baran-Marszak F, Cymbalista F, Carrasco RD, Wu CJ. A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation. Cancer Cell. 2021 Mar 8;39(3):380-393.e8. https://doi.org/10.1016/j.ccell.2021.02.003
Rogers KA, Thompson PA, Allan JN, Coleman M, Sharman JP, Cheson BD, Jones D, Izumi R, Frigault MM, Quah C, Raman RK, Patel P, Wang MH, Kipps TJ. Phase 2 study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. Haematologica. 2021 Mar 18. [Epub ahead of print] https://doi.org/10.3324/haematol.2020.272500
Stevenson FK, Forconi F, Kipps TJ. Exploring the Pathways to Chronic Lymphocytic Leukemia. Blood. 2021 Jun 1. [Epub ahead of print] https://doi.org/10.1182/blood.2020010029
Ma S, Seymour JF, Brander DM, Kipps TJ, Choi MY, Anderson MA, Humphrey K, Al Masud A, Pesko J, Nandam R, Salem AH, Chyla B, Arzt J, Jacobson A, Kim SY, Roberts AW. Efficacy of venetoclax plus rituximab for relapsed CLL: Five-year follow-up of continuous or limited-duration therapy. Blood. 2021 Jun 3:blood.2020009578. [Epub ahead of print]. https://doi.org/10.1182/blood.2020009578
Davids MS, Roberts AW, Kenkre VP, Wierda WG, Kumar A, Kipps TJ, Boyer M, Salem AH, Pesko JC, Arzt JA, Mantas M, Kim SY, Seymour JF. Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study. Clin Cancer Res. 2021 Jun 3. [Epub ahead of print]. https://doi.org/10.1158/1078-0432.CCR-20-4842
Penter L, Gohil SH, Lareau C, Ludwig LS, Parry EM, Huang T, Li S, Zhang W, Livitz D, Leshchiner I, Parida L, Getz G, Rassenti LZ, Kipps TJ, Brown JR, Davids MS, Neuberg DS, Livak KJ, Sankaran VG, Wu CJ. Longitudinal single-cell dynamics of chromatin accessibility and mitochondrial mutations in chronic lymphocytic leukemia mirror disease history. Cancer Discov. 2021 Jun 10:candisc.0276.2021. [Epub ahead of print]. https://doi.org/10.1158/2159-8290.CD-21-0276
Kleinstern G, Weinberg JB, Parikh SA, Braggio E, Achenbach SJ, Robinson DP, Norman AD, Rabe KG, Boddicker NJ, Vachon CM, Lesnick CE, Call TG, Brander DM, Rassenti LZ, Kipps TJ, Olson JE, Cerhan JR, Kay NE, Furman RR, Hanson CA, Shanafelt TD, Slager SL. Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans. Leukemia. 2021 Jul 20. [Epub ahead of print]. https://doi.org/10.1038/s41375-021-01344-9

Page last updated on August 3 2021.

Introduction

Collected Works

1977

1978

1979

1980

1983

1985

1986

1987

1988

1989

1990

1991

1992

1993

1994

1995

1996

1997

1998

1999

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

Share this:

Like this: